var title_f41_23_42352="Histology lung 1B answer";
var content_f41_23_42352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary histoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Silver-stained section of same lung tissue (x1000) shows the blackish staining yeast forms of Histoplasma capsulatum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42352=[""].join("\n");
var outline_f41_23_42352=null;
var title_f41_23_42353="Patient information: Chronic pelvic pain in women (The Basics)";
var content_f41_23_42353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15432\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"          Digestive system",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\">",
"           Anatomy of the urinary tract",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/55/32627\">",
"         Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chronic pelvic pain in women (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chronic-pelvic-pain-in-women-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H463910048\">",
"      <span class=\"h1\">",
"       What is chronic pelvic pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chronic pelvic pain is internal pain in the area bellow the belly button that lasts 6 months or longer. It often involves the sex organs (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"mobipreview.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ). Sometimes the pain is tied to problems with the intestines (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"mobipreview.htm?28/27/29107\">",
"       figure 2",
"      </a>",
"      ) or the bladder (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"mobipreview.htm?26/28/27072\">",
"       figure 3",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H463910055\">",
"      <span class=\"h1\">",
"       What causes chronic pelvic pain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chronic pelvic pain can be caused by several medical conditions, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Endometriosis",
"        </strong>",
"        &ndash; This is a condition in which cells that should exist only in the uterus begin to grow outside the uterus. Women who have endometriosis often have very painful periods. They also sometimes have problems getting pregnant.",
"       </li>",
"       <li>",
"        <strong>",
"         Chronic pelvic inflammatory disease",
"        </strong>",
"        &ndash; This condition happens after a related condition called &ldquo;acute pelvic inflammatory disease&rdquo; (PID). Acute PID is often caused by an infection that you catch during sex. Some women have pain long after the acute infection. They also often have problems getting pregnant.",
"       </li>",
"       <li>",
"        <strong>",
"         Irritable bowel syndrome (IBS)",
"        </strong>",
"        &ndash; This is a condition that affects the intestines and causes both pain and problems with bowel movements. Women with IBS usually also have constipation, diarrhea, or both.",
"       </li>",
"       <li>",
"        <strong>",
"         Painful bladder syndrome and interstitial cystitis",
"        </strong>",
"        &ndash; These are conditions that cause the bladder to hurt when it is getting full. Women with these conditions often feel better when they empty their bladder, so they go to the bathroom often.",
"       </li>",
"       <li>",
"        <strong>",
"         Pelvic floor pain",
"        </strong>",
"        &ndash; Pelvic floor pain involves the muscles in the pelvic area, which can become tight and tender.",
"       </li>",
"       <li>",
"        <strong>",
"         Fibromyalgia",
"        </strong>",
"        &ndash; This is a pain disorder that causes pain in several parts of the body, not just the pelvic area.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H463910062\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have pelvic pain, your doctor or nurse will probably give you a regular pelvic exam. He or she might also order some blood or urine tests. Depending on your situation, you might also have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Pelvic ultrasound",
"        </strong>",
"        &ndash; This test uses sound waves to create an image of your pelvic organs. Doctors can use this test to spot fluid-filles sacs (called cysts), abnormal growths, and other problems.",
"       </li>",
"       <li>",
"        <strong>",
"         Laparoscopy",
"        </strong>",
"        &ndash; This is a procedure done in an operating room. The doctor makes a small incision near your belly button and inserts a device called a laparoscope. Then the doctor looks through the laparoscope to see if he or she can find the cause of your pain.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H463910069\">",
"      <span class=\"h1\">",
"       How is pelvic pain treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what is causing your pelvic pain. Possible treatments could include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain medicines",
"       </li>",
"       <li>",
"        Birth control pills",
"       </li>",
"       <li>",
"        Change in diet",
"       </li>",
"       <li>",
"        Physical therapy to help loosen or relax the muscles in the pelvic area",
"       </li>",
"       <li>",
"        &ldquo;Talk&rdquo; therapy or other types of counseling, which can help you learn ways to cope and manage the pain",
"       </li>",
"       <li>",
"        Surgery to remove the cause of the pain, if possible",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some women benefit from treatment at a pain clinic. Pain clinics offer special treatments for pain, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain medicines that come in shots",
"       </li>",
"       <li>",
"        Acupuncture, which involves having needles inserted into your skin",
"       </li>",
"       <li>",
"        Devices that block pain using mild electrical shocks",
"       </li>",
"       <li>",
"        Biofeedback, a technique that helps you learn how to control certain muscles",
"       </li>",
"       <li>",
"        Relaxation exercises",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H463910076\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/55/32627?source=see_link\">",
"       Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/23/42353?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15432 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42353=[""].join("\n");
var outline_f41_23_42353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H463910048\">",
"      What is chronic pelvic pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H463910055\">",
"      What causes chronic pelvic pain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H463910062\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H463910069\">",
"      How is pelvic pain treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H463910076\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15432\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"       Digestive system",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\">",
"        Anatomy of the urinary tract",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/55/32627?source=related_link\">",
"      Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_23_42354="AIDS-related Kaposis sarcoma - penis";
var content_f41_23_42354=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AIDS-related Kaposi's sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A vascular papule consistent with Kaposi's sarcoma is present on the penis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42354=[""].join("\n");
var outline_f41_23_42354=null;
var title_f41_23_42355="Quinagolide: Drug information";
var content_f41_23_42355=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quinagolide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/32/8708?source=see_link\">",
"    see \"Quinagolide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4800585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Norprolac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4800586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Hyperprolactinemia Agent, Dopamine (D2) Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4800623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hyperprolactinemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Initial: 0.025 mg/day for 3 days followed by 0.05 mg/day for 3 days (starter pack)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maintenance (beginning on day 7): 0.075 mg/day; if needed, a further stepwise titration of dose may occur with intervals of at least 1 week minimum; usual maintenance range: 0.075-0.15 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum dose: Titrate by increasing dose by 0.075-0.15 mg/day no more frequently than every 4 weeks, up to 0.9 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F4801577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4800624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4800625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Combination package:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Norprolac&reg; [starter pack]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Tablet, as hydrochloride: 0.025 mg (3s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Tablet, as hydrochloride: 0.05 mg (3s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Tablet, as hydrochloride: 0.075 mg (3s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Norprolac&reg;: 0.075 mg, 0.15 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4800626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with snack at bedtime. Nausea and vomiting may be alleviated by premedicating with a peripheral dopamine antagonist.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2638239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hyperprolactinemia due to prolactin-secreting pituitary tumors (microadenoma or macroadenoma) or idiopathic in nature",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4800596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness, fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (2%), flushing (1%), hypotension (1%), palpitation (1%), syncope (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Sedation (3%), insomnia (2%), concentration decreased (1%), malaise (1%), mood lability (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain/discomfort (3%), constipation (3%), anorexia (2%), dyspepsia (2%), diarrhea (1%), weight gain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Breast pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (3%), extremity pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasal congestion (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute psychosis, bilirubin increased, creatine phosphokinase increased, hematocrit decreased, hemoglobin decreased, neutropenia, potassium increased, somnolence, transaminases increased, triglycerides increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4800591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to quinagolide or any component of the formulation; hepatic or renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4800592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fertility changes: Use caution in women of childbearing age; restoration of fertility may occur; patients not wanting to conceive should implement a reliable method of birth control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; G.I. distress: Use may be associated with frequent (but transient) nausea and vomiting early in therapy; during initial therapy, premedication with a peripheral dopamine antagonist may alleviate these effects and improve tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension: Hypotensive episodes along with syncope may occur with the onset of therapy; monitor blood pressure early in therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sedation: Use may be associated with sudden sleep onset and somnolence (especially in patients with Parkinson&rsquo;s disease); patients should be cautioned about performing dangerous tasks such as operating heavy machinery or driving. Use with other agents known to induce somnolence or sleep may be expected to potentiate these risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Psychosis: Use with caution in patients with prior psychotic disorders; the onset of acute psychosis has rarely been observed with use of quinagolide (reversible upon discontinuation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiotherapy/Surgery: Treatment with quinagolide may not exclude the need for radiation and/or surgical intervention if appropriate.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F4800603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4800602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4800606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May reduce tolerability of quinagolide.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4800587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies revealed no embryotoxic or teratogenic effects. Fertility may be restored with treatment. Discontinue use with confirmed pregnancy unless medically necessary to continue. No increase in the incidence of abortion has been seen with a discontinuation of the drug during pregnancy. The reinstitution of therapy may be necessary in patients who display symptoms of tumor enlargement (headaches, visual field changes).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4800589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4800590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     By inhibiting prolactin secretion, quinagolide suppresses lactation.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4800628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, basic metabolic panel, transaminases, triglycerides, prolactin levels; blood pressure; sedation, mental changes",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Norprolac (AT, CA, CH, DE, ES, FI, FR, GB, GR, HK, IL, MX, NL, NO, SE, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4800609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective dopamine D",
"     <sub>",
"      2",
"     </sub>",
"     receptor agonist that exerts a direct inhibitory effect on cells (lactotrophs) in the anterior pituitary gland which synthesize and secrete prolactin; not an ergot alkaloid",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4800611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 2 hours; maximum effect: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: &gt;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 100 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; via conjugation (glucuronide and sulfate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 11.5 hours; steady state: 17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (50%); feces (40%); &gt;95% as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barlier A and Jacquet P, &ldquo;Quinagolide &minus; A Valuable Treatment Option for Hyperprolactinaemia,&rdquo;",
"      <i>",
"       Eur J Endocrinol",
"      </i>",
"      , 2006, 154(2):187-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/23/42355/abstract-text/16452531/pubmed\" id=\"16452531\" target=\"_blank\">",
"        16452531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bronstein M, &ldquo;Prolactinomas and Pregnancy&rdquo;,",
"      <i>",
"       Pituitary",
"      </i>",
"      , 2005, 8(1):31-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/23/42355/abstract-text/16411066/pubmed\" id=\"16411066\" target=\"_blank\">",
"        16411066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DiSarno A, Landi ML, Marzullo P, et al, &ldquo;The Effect of Quinagolide and Cabergoline, Two Selective Dopamine Receptor Type 2 Agonists, in the Treatment of Prolactinomas,&rdquo;",
"      <i>",
"       Clin Endocrinol",
"      </i>",
"      (Oxf), 2000, 53(1):53-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/23/42355/abstract-text/10931080/pubmed\" id=\"10931080\" target=\"_blank\">",
"        10931080",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schultz PN, Ginsberg L, McCutcheon IE, et al, &ldquo;Quinagolide in the Management of Prolactinoma,&rdquo;",
"      <i>",
"       Pituitary",
"      </i>",
"      , 2000, 3(4):239-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/23/42355/abstract-text/11788012/pubmed\" id=\"11788012\" target=\"_blank\">",
"        11788012",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10227 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42355=[""].join("\n");
var outline_f41_23_42355=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800585\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800586\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800623\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801577\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800624\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800625\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950139\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234287\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800626\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638239\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800596\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800591\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800592\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800603\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800602\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800606\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800587\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800589\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800590\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800628\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369778\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800609\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4800611\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10227\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10227|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/32/8708?source=related_link\">",
"      Quinagolide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_23_42356="Methyltestosterone: Patient drug information";
var content_f41_23_42356=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methyltestosterone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/36/3652?source=see_link\">",
"     see \"Methyltestosterone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Android&reg;;",
"     </li>",
"     <li>",
"      Methitest&trade;;",
"     </li>",
"     <li>",
"      Testred&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691763",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breast cancer in women.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691805",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat delays in a man's growth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691903",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat impotence.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691941",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low testosterone levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methyltestosterone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are man and have breast cancer or prostate cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697732",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug and for 1 month after stopping this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698036",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Emotional ups and downs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698674",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For men, enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698098",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, breast soreness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Erection that lasts more than 4 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698664",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, a deep voice, facial hair, pimples, or period changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cheek tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695523",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place tablet in your mouth above a rear molar tooth between the upper cheek and gum and let melt.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694694",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11986 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-AD25BEE436-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42356=[""].join("\n");
var outline_f41_23_42356=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195469\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029267\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029266\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029271\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029272\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029274\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029269\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029270\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029275\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029276\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/36/3652?source=related_link\">",
"      Methyltestosterone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_23_42357="Lamina propria invasion";
var content_f41_23_42357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Invasion of the lamina propria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A: In early invasive urothelial carcinoma (superficial disease, pT1), foci of invasion are characterized by nests, clusters, or single urothelial cells within lamina propria (10x). B: The invasive nests may induce a desmoplastic stromal response (20x). C: Foci of invasive tumor within the lamina propria may be associated with retraction artifact, mimicking vascular invasion (40x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42357=[""].join("\n");
var outline_f41_23_42357=null;
var title_f41_23_42358="Complex cystic small renal mass";
var content_f41_23_42358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F87864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F87864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Complex cystic small renal mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT without (A) then with (B) intravenous contrast shows a 3.8 cm right renal cyst with a mural nodule (circle) that increases &gt;15 Hounsfield units (HU) in attenuation with contrast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42358=[""].join("\n");
var outline_f41_23_42358=null;
var title_f41_23_42359="Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction";
var content_f41_23_42359=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/23/42359/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/23/42359/contributors\">",
"     Namita Roy-Chowdhury, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/23/42359/contributors\">",
"     Xia Wang, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/23/42359/contributors\">",
"     Jayanta Roy-Chowdhury, MD, MRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/23/42359/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/23/42359/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/23/42359/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/23/42359/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/23/42359/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolism of bilirubin by the liver is comprised of four distinct but interrelated stages. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27943?source=see_link\">",
"     \"Bilirubin metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uptake from the circulation",
"     </li>",
"     <li>",
"      Intracellular storage",
"     </li>",
"     <li>",
"      Conjugation with glucuronic acid",
"     </li>",
"     <li>",
"      Biliary excretion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normally, approximately 96 percent of plasma bilirubin is unconjugated. Abnormalities in any one or more of the above steps can result in hyperbilirubinemia in which there is either an elevation in unconjugated bilirubin alone or of both unconjugated and conjugated bilirubin. Complex clinical disorders, such as hepatitis or cirrhosis, can affect multiple processes, resulting in the accumulation of both unconjugated and conjugated bilirubin. In these settings, the proportion of conjugated bilirubin in plasma increases. In contrast, the unconjugated fraction alone is increased with bilirubin overproduction (as with hemolysis) without liver disease and with inherited or acquired disorders that specifically affect bilirubin uptake or glucuronidation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7065?source=see_link\">",
"     \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common causes of unconjugated hyperbilirubinemia are bilirubin overproduction, Gilbert's syndrome, and neonatal jaundice. This topic will review the first two disorders with particular emphasis on Gilbert's syndrome. Crigler-Najjar syndromes type I and II, which are rare inherited diseases associated with unconjugated hyperbilirubinemia, and neonatal jaundice are discussed separately, as is an approach to the patient with jaundice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6201?source=see_link\">",
"     \"Crigler-Najjar syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=see_link\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BILIRUBIN OVERPRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most disorders associated with increased bilirubin production are due to hemolysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    .) Transient elevation of the unconjugated form of bilirubin can also occur during absorption of large hematomas. Examples of disorders associated with hemolysis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diseases associated with abnormal red cell morphology leading to their premature destruction (eg, sickle cell anemia and hereditary spherocytosis)",
"     </li>",
"     <li>",
"      Mechanical hemolysis (eg, thrombotic thrombocytopenic",
"      <span class=\"nowrap\">",
"       purpura/hemolytic-uremic",
"      </span>",
"      syndrome)",
"     </li>",
"     <li>",
"      Autoimmune hemolytic anemia due to warm or cold agglutinins",
"     </li>",
"     <li>",
"      Toxic or idiosyncratic disorders (eg, drug toxicity)",
"     </li>",
"     <li>",
"      Diseases associated with ineffective erythropoiesis leading to destruction of red cell precursors in the bone marrow (eg, thalassemia minor)",
"     </li>",
"     <li>",
"      Hereditary rare anemias termed \"congenital dyserythropoietic anemias\", which are associated with ineffective erythropoiesis, intramedullary normoblastic hyperplasia, and secondary hemochromatosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hyperbilirubinemia in these settings is predominantly unconjugated (indirect), and the plasma bilirubin concentration rarely exceeds 3 to 4",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Although a small amount of conjugated (direct) bilirubin can accumulate in the serum, the proportion of the conjugated form stays within the normal limits (about 4 percent of total bilirubin). Higher levels may be seen when coexisting abnormalities of hepatobiliary function are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GILBERT'S SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common inherited disorder of bilirubin glucuronidation is Gilbert's syndrome, which has also been called \"constitutional hepatic dysfunction\" and \"familial nonhemolytic jaundice\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/2\">",
"     2",
"    </a>",
"    ]. Although many patients present as isolated cases, the condition is known to run in families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uridinediphosphoglucuronate glucuronosyltransferases (UGTs) are a family of enzymes that mediate glucuronidation of various endogenous and exogenous compounds (",
"    <a class=\"graphic graphic_figure graphicRef52393 \" href=\"mobipreview.htm?30/51/31536\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27943?source=see_link\">",
"     \"Bilirubin metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Characterization of the UGT1A gene locus has permitted an understanding of the molecular defects responsible for Gilbert's syndrome. The mutation responsible for these cases is in the promoter region, upstream to exon 1 of the gene encoding bilirubin-UGT, the isoform that conjugates bilirubin to glucuronic acid (UGT1A1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/4\">",
"     4",
"    </a>",
"    ]. The normal sequence of the TATAA element within the promoter is A[TA]6TAA. Caucasian and black subjects with Gilbert's syndrome are homozygous for a longer version of the TATAA sequence, A[TA]7TAA, which causes reduced production of bilirubin-UGT (",
"    <a class=\"graphic graphic_figure graphicRef73505 \" href=\"mobipreview.htm?32/44/33487\">",
"     figure 2",
"    </a>",
"    ). UGT1A1 alleles bearing this variant promoter are termed UGT1A1*28. This defect is different from that in the Crigler-Najjar syndromes in which bilirubin-UGT is either absent or produced in an abnormal form with reduced or no activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6201?source=see_link\">",
"     \"Crigler-Najjar syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 9 percent of individuals of the general population in the Western world are homozygous for the variant promoter, and approximately 30 percent are heterozygous. The longer TATAA element has been found in all subjects with Gilbert's syndrome studied in the United States, Europe, and countries of the Middle East and South Asia. However, other factors are probably involved in the expression of the Gilbert's phenotype since not all patients who are homozygous for the variant promoter develop hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, in the Japanese population, other mutations within the coding regions of the UGT1A1 gene can cause the Gilbert's phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the high frequency of the Gilbert type promoter, some heterozygous carriers of structural mutations that cause Crigler-Najjar syndrome, types I or II also carry the Gilbert's type of TATAA element on their normal allele. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6201?source=see_link\">",
"     \"Crigler-Najjar syndrome\"",
"    </a>",
"    .) Such combined defects can lead to severe hyperbilirubinemia, occasionally causing kernicterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This also explains the frequent finding of intermediate levels of hyperbilirubinemia in the family members of patients with Crigler-Najjar syndrome, types I and II.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gilbert's syndrome manifests only in people who are homozygous for the variant promoter. As a result, its inheritance is most consistent with an autosomal recessive trait (",
"    <a class=\"graphic graphic_table graphicRef80818 \" href=\"mobipreview.htm?27/11/27836\">",
"     table 1",
"    </a>",
"    ). However, heterozygotes for the Gilbert's genotype have higher average plasma bilirubin concentrations compared to those with two wild-type alleles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gilbert's syndrome is usually diagnosed in young adults who present with mild, predominantly unconjugated hyperbilirubinemia. It is rarely diagnosed prior to puberty when alterations in sex steroid concentrations affect bilirubin metabolism, leading to increased plasma bilirubin concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/9\">",
"     9",
"    </a>",
"    ]. The disorder is more commonly diagnosed in males, possibly due to a relatively higher level of daily bilirubin production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physical examination is usually unrevealing except for icterus. However, as discussed below, situations that exaggerate hyperbilirubinemia may bring the patient to medical attention and have corresponding physical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Determinants of plasma bilirubin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory tests are usually normal in patients with Gilbert's syndrome, except for hyperbilirubinemia (",
"    <a class=\"graphic graphic_table graphicRef80818 \" href=\"mobipreview.htm?27/11/27836\">",
"     table 1",
"    </a>",
"    ). Serum bilirubin levels fluctuate; they are usually less than 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and can be normal. Certain associated pathologic conditions or physiologic events can increase the plasma bilirubin concentrations to higher values, but usually less than 6",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemolysis, which increases bilirubin production.",
"     </li>",
"     <li>",
"      Fasting, which causes a two- to threefold increase in the plasma bilirubin concentration within 48 hours after the total daily calorie intake has been reduced to 400 kcal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. A similar rise in bilirubin occurs in patients with Gilbert's syndrome who receive a normocaloric diet without lipids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/12\">",
"       12",
"      </a>",
"      ]. The bilirubin concentration returns to baseline within 12 to 24 hours after resuming a normal diet.",
"      <br/>",
"      <br/>",
"      The cause of hyperbilirubinemia during fasting is probably multifactorial. Several causes have been hypothesized to contribute, including an increased bilirubin load due to the release of bilirubin contained within adipocytes, decreased conjugation due to depletion of UDP-GA (which serves as a cosubstrate in glucuronidation), and enhanced cycling of bilirubin by the enterohepatic circulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/13-16\">",
"       13-16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intercurrent febrile illnesses, physical exertion or stress, which probably causes hyperbilirubinemia by the same mechanisms as fasting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Within three hours after the intravenous administration of nicotinic acid&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/17\">",
"       17",
"      </a>",
"      ]. The mechanism is unknown, but may be due to an increase in bilirubin formation in the spleen and enhanced uptake by the liver [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A relationship to menses has been reported in two women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also settings in which plasma bilirubin concentrations are reduced in patients with Gilbert's syndrome. These include the administration of corticosteroids, which increase hepatic uptake of bilirubin, or hepatic enzyme inducers (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    and clofibrate), which normalize plasma bilirubin concentrations within one to two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Specialized tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specialized tests can demonstrate a number of abnormalities in hepatic function including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in hepatic bilirubin-UGT activity, which is approximately 30 percent of normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 14 to 34 percent increase in the proportion of monoconjugated bile pigments, which normally represents only 7 to 10 percent of the total bile pigments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mild and fully compensated hemolysis detected only by sensitive measures of red cell survival have been reported in up to 40 percent of patients with Gilbert's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, hemolysis is not a part of Gilbert's syndrome; thus, this observation is more likely to be accounted for by the increased bilirubin production due to hemolysis, which accentuates the jaundice and brings Gilbert's patients to medical attention.",
"   </p>",
"   <p>",
"    Histopathologically, the liver is normal except for nonspecific accumulation of lipofuscin pigment in the centrilobular zones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/29\">",
"     29",
"    </a>",
"    ]. Minor abnormalities may be seen by electron microscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with Gilbert's syndrome are asymptomatic or have nonspecific complaints (such as malaise, abdominal discomfort, or fatigue) of uncertain relation to the elevated plasma bilirubin concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/30\">",
"     30",
"    </a>",
"    ]. The long-term outcome is expected to be similar to that in the general population. Although Gilbert's syndrome is benign in adults, the Gilbert genotype is associated with increased severity and duration of neonatal jaundice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have suggested that mildly increased serum bilirubin levels, such as those associated with Gilbert's syndrome, may be beneficial because of the antioxidative effect of bilirubin. The incidence of atherosclerotic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/33\">",
"     33",
"    </a>",
"    ], colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/34\">",
"     34",
"    </a>",
"    ], and cancer-related mortality in general [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/35\">",
"     35",
"    </a>",
"    ] have been reported to have an inverse relation with serum bilirubin levels. Furthermore, overweight children developing non-alcoholic fatty liver disease (NAFLD) were found to have lower mean serum bilirubin levels than those who did not develop NAFLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/36\">",
"     36",
"    </a>",
"    ]. The protective effect does not appear to be specific to the UGT1A1*28 genotype, but is related directly to serum bilirubin levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Alteration in drug metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since UGT1A1 is involved in the glucuronidation of estrogen and several important drugs and carcinogens, individuals with Gilbert's syndrome may be more susceptible to the toxic effect of substances that require UGT1A1-mediated hepatic glucuronidation prior to excretion. Examples include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/49/42774?source=see_link\">",
"     tolbutamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Diminished excretion of these drugs could potentially cause their accumulation and increase toxic effects. Studies based on intravenous administration of acetaminophen found reduced glucuronidation of the drug in subjects with Gilbert's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/33\">",
"     33",
"    </a>",
"    ], but no such correlation was found after oral administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/35,37\">",
"     35,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More clear evidence of increased risk of toxicity in patients with Gilbert's syndrome has been observed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      , a promising antitumor agent. Its active metabolite, SN-38, is glucuronidated in the liver, mainly by the bilirubin-UGT isoform and excreted in the bile. The major dose-limiting toxicity is diarrhea. In Gunn rats (an animal model of Crigler-Najjar syndrome), in patients with Gilbert's and Crigler-Najjar syndrome, as well as in patients who inherit certain UGT 1A1 polymorphisms, reduced glucuronidation of SN-38 leads to an increased incidence of diarrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. The symptoms can be severe enough to warrant switching to other drugs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H22#H22\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Pharmacokinetic variability'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, some drugs may cause isolated hyperbilirubinemia without alteration of other liver functions. As an example, one report described the development of isolated hyperbilirubinemia during the treatment of hepatitis C with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/41\">",
"     41",
"    </a>",
"    ]. In such cases, it is not necessary to discontinue the therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important aspect of the diagnosis of Gilbert's syndrome is recognition of the disorder without subjecting patients to invasive and unnecessary testing. The diagnosis has traditionally been established based upon the clinical setting of mild unconjugated hyperbilirubinemia possibly provoked by one of the factors discussed above in patients with no apparent liver disease. A presumptive diagnosis can be made in patients with the following features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unconjugated hyperbilirubinemia on repeated testing",
"     </li>",
"     <li>",
"      A normal complete blood count, blood smear, and reticulocyte count",
"     </li>",
"     <li>",
"      Normal liver function tests (plasma aminotransferases and alkaline phosphatase concentrations)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis is definitive in patients who continue to have normal laboratory studies (other than the elevation in plasma bilirubin) during the next 12 to 18 months. As discussed above, the diagnosis is also supported by observing a rise in the plasma bilirubin concentration following a low lipid, 400 kcal diet or after the administration of intravenous nicotinic acid&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/14,17,19\">",
"     14,17,19",
"    </a>",
"    ]. However, these provocative tests are seldom necessary in clinical practice.",
"   </p>",
"   <p>",
"    Genetic testing can confirm the diagnosis in settings where there is diagnostic confusion. It is currently available at some clinical laboratories (see",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific therapy is required for patients who are diagnosed with Gilbert's syndrome. The most important aspect of the care of these patients is recognition of the disorder and its inconsequential nature, except for an increased incidence of side effects from certain drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    . Its mode of inheritance should also be discussed to prevent unnecessary testing in family members.",
"   </p>",
"   <p>",
"    Case reports have described patients with Gilbert's syndrome who developed severe unconjugated hyperbilirubinemia. Such patients typically have an additional mutation in the UGT1A1 promoter, are heterozygous carriers of a Crigler-Najjar-type structural mutation, or have a coexisting condition predisposing the severe hyperbilirubinemia (such as a hematologic disorder leading to hemolysis, eg, spherocytosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/47\">",
"     47",
"    </a>",
"    ]. A case series of two such patients (one with hereditary spherocytosis and another with an additional mutation in UGT1A1) described successful treatment of the hyperbilirubinemia with rifampicin, which acts by induction of UGT1A1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42359/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/28/21953?source=see_link\">",
"       \"Patient information: Gilbert&rsquo;s syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/16/3328?source=see_link\">",
"       \"Patient information: Gilbert's syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most disorders associated with increased bilirubin production are due to hemolysis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=see_link\">",
"       \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most common inherited disorder of bilirubin glucuronidation is Gilbert's syndrome, which is usually diagnosed in young adults who present with mild, predominantly unconjugated hyperbilirubinemia.",
"     </li>",
"     <li>",
"      A presumptive diagnosis of Gilbert's syndrome may be made in patients with unconjugated hyperbilirubinemia on repeated testing who have a normal complete blood count, blood smear, and reticulocyte count and normal liver function tests (plasma aminotransferases and alkaline phosphatase concentrations). The diagnosis is definitive in patients who continue to have normal laboratory studies (other than the elevation in plasma bilirubin) during the next 12 to 18 months.",
"     </li>",
"     <li>",
"      Genetic testing can confirm the diagnosis in settings where there is diagnostic confusion. It is currently available at some clinical laboratories (see",
"      <a class=\"external\" href=\"file://www.genetests.org/\">",
"       www.genetests.org",
"      </a>",
"      ). The University of Chicago Genetics Laboratory (telephone 1-888-UC-GENES, web address",
"      <a class=\"external\" href=\"file://www.genes.uchicago.edu/\">",
"       www.genes.uchicago.edu",
"      </a>",
"      ) is one option.",
"     </li>",
"     <li>",
"      No specific therapy is required for patients who are diagnosed with Gilbert's syndrome. The most important aspect of the care of these patients is recognition of the disorder and its inconsequential nature, except for an increased incidence of side effects from certain drugs, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Alteration in drug metabolism'",
"      </a>",
"      above.) Its mode of inheritance should also be discussed to prevent unnecessary testing in family members. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Inheritance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114101113\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's many contributions to our program, in particular, his work on this topic as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Berk PD, Jones EA, Howe RB, et al. Disorders of bilirubin metabolism. In: Metabolic Control and Disease, 8th ed, Bondy PK, Rosenberg LE (Eds), Saunders, Philadelphia 1980. p.1009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/2\">",
"      Gilbert A, Lereboullet P. La cholamae simple familiale. Sem Med 1901; 21:241.",
"     </a>",
"    </li>",
"    <li>",
"     Thompson RP. Genetic transmission of Gilbert's syndrome. In: Familial Hyperbilirubinemia, Okolicsanyi L (Ed), Wiley, New York 1981. p.91.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/4\">",
"      Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/5\">",
"      Aono S, Adachi Y, Uyama E, et al. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet 1995; 345:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/6\">",
"      Koiwai O, Nishizawa M, Hasada K, et al. Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase. Hum Mol Genet 1995; 4:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/7\">",
"      Chalasani N, Chowdhury NR, Chowdhury JR, Boyer TD. Kernicterus in an adult who is heterozygous for Crigler-Najjar syndrome and homozygous for Gilbert-type genetic defect. Gastroenterology 1997; 112:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/8\">",
"      Kadakol A, Sappal BS, Ghosh SS, et al. Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus. J Med Genet 2001; 38:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/9\">",
"      Muraca M, Fevery J. Influence of sex and sex steroids on bilirubin uridine diphosphate-glucuronosyltransferase activity of rat liver. Gastroenterology 1984; 87:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/10\">",
"      Felsher BF, Rickard D, Redeker AG. The reciprocal relation between caloric intake and the degree of hyperbilirubinemia in Gilbert's syndrome. N Engl J Med 1970; 283:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/11\">",
"      Barrett PV. Hyperbilirubinemia of fasting. JAMA 1971; 217:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/12\">",
"      Gollan JL, Bateman C, Billing BH. Effect of dietary composition on the unconjugated hyperbilirubinaemia of Gilbert's syndrome. Gut 1976; 17:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/13\">",
"      Cowan RE, Thompson RP, Kaye JP, Clark GM. The association between fasting hyperbilirubinaemia and serum non-esterified fatty acids in man. Clin Sci Mol Med 1977; 53:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/14\">",
"      Felsher BF, Carpio NM, VanCouvering K. Effect of fasting and phenobarbital on hepatic UDP-glucuronic acid formation in the rat. J Lab Clin Med 1979; 93:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/15\">",
"      Kotal P, V&iacute;tek L, Fevery J. Fasting-related hyperbilirubinemia in rats: the effect of decreased intestinal motility. Gastroenterology 1996; 111:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/16\">",
"      Brink MA, M&eacute;ndez-S&aacute;nchez N, Carey MC. Bilirubin cycles enterohepatically after ileal resection in the rat. Gastroenterology 1996; 110:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/17\">",
"      Fromke VL, Miller D. Constitutional hepatic dysfunction (CHD; Gilbert's disease); a review with special reference to a characteristic increase and prolongation of the hyperbilirubinemic response to nicotinic acid. Medicine (Baltimore) 1972; 51:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/18\">",
"      GYDELL K. Nicotinic acid induced hyperbilirubinemia and hypersideremia. I. Observations in hemolytic disease and allied conditions. Acta Med Scand 1959; 164:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/19\">",
"      Gentile S, Tiribelli C, Persico M, et al. Dose dependence of nicotinic acid-induced hyperbilirubinemia and its dissociation from hemolysis in Gilbert's syndrome. J Lab Clin Med 1986; 107:166.",
"     </a>",
"    </li>",
"    <li>",
"     Cobelli C, Ruggeri A, Toffolo G. BSP vs bilirubin kinetics in Gilbert's syndrome. In: Familial Hyperbilirubinemia, Okolicsanyi L (Ed), Wiley, New York 1981. p.121.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/21\">",
"      Ohkubo H, Okuda K, Iida S. Effects of corticosteroids on bilirubin metabolism in patients with Gilbert's syndrome. Hepatology 1981; 1:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/22\">",
"      Black M, Sherlock S. Treatment of Gilbert's syndrome with phenobarbitone. Lancet 1970; 1:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/23\">",
"      Kutz K, Kandler H, Gugler R, Fevery J. Effect of clofibrate on the metabolism of bilirubin, bromosulphophthalein and indocyanine green and on the biliary lipid composition in Gilbert's syndrome. Clin Sci (Lond) 1984; 66:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/24\">",
"      Black M, Billing BH. Hepatic bilirubin udp-glucuronyl transferase activity in liver disease and gilbert's syndrome. N Engl J Med 1969; 280:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/25\">",
"      Auclair C, Hakim J, Boivin P, et al. Bilirubin and paranitrophenol glucuronyl transferase activities of the liver in patients with Gilbert's syndrome An attempt at a biochemical breakdown of the Gilbert's syndrome. Enzyme 1976; 21:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/26\">",
"      Fevery J, Blanckaert N, Heirwegh KP, et al. Unconjugated bilirubin and an increased proportion of bilirubin monoconjugates in the bile of patients with Gilbert's syndrome and Crigler-Najjar disease. J Clin Invest 1977; 60:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/27\">",
"      Powell LW, Billing BH, Williams HS. An assessment of red cell survival in idiopathic unconjugated hyperbilirubinaemia (Gilbert's syndrome) by the use of radioactive diisopropylfluorophosphate and chromium. Australas Ann Med 1967; 16:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/28\">",
"      Blueger AF, Krupnikova EZ, Sondore VY, Semushina EP. Study of the etiology and pathogenesis of low grade nonhemolytic unconjugated hyperbilirubinemia (Gilbert's disease). Acta Hepatogastroenterol (Stuttg) 1977; 24:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/29\">",
"      SAGILD U, DALGAARD OZ, TYGSTRUP N. Constitutional hyperbilirubinemia with unconjugated bilirubin in the serum and lipochrome-like pigment granules in the liver. Ann Intern Med 1962; 56:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/30\">",
"      Powell LW, Hemingway E, Billing BH, Sherlock S. Idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). A study of 42 families. N Engl J Med 1967; 277:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/31\">",
"      Roy-Chowdhury N, Deocharan B, Bejjanki HR, et al. Presence of the genetic marker for Gilbert syndrome is associated with increased level and duration of neonatal jaundice. Acta Paediatr 2002; 91:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/32\">",
"      Monaghan G, McLellan A, McGeehan A, et al. Gilbert's syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn. J Pediatr 1999; 134:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/33\">",
"      de Morais SM, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 1992; 102:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/34\">",
"      Carulli N, Ponz de Leon M, Mauro E, et al. Alteration of drug metabolism in Gilbert's syndrome. Gut 1976; 17:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/35\">",
"      Ullrich D, Sieg A, Blume R, et al. Normal pathways for glucuronidation, sulphation and oxidation of paracetamol in Gilbert's syndrome. Eur J Clin Invest 1987; 17:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/36\">",
"      Lin YC, Chang PF, Hu FC, et al. Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. Pediatrics 2009; 124:e1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/37\">",
"      Rauchschwalbe SK, Z&uuml;hlsdorf MT, Wensing G, Kuhlmann J. Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype. Int J Clin Pharmacol Ther 2004; 42:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/38\">",
"      Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/39\">",
"      Burchell B, Soars M, Monaghan G, et al. Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases. Toxicol Lett 2000; 112-113:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/40\">",
"      Glimelius B, Garmo H, Berglund A, et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 2011; 11:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/41\">",
"      Deterding K, Gr&uuml;ngreiff K, Lankisch TO, et al. Gilbert's syndrome and antiviral therapy of hepatitis C. Ann Hepatol 2009; 8:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/42\">",
"      Roda A, Roda E, Sama C, et al. Serum primary bile acids in Gilbert's syndrome. Gastroenterology 1982; 82:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/43\">",
"      Vierling JM, Berk PD, Hofmann AF, et al. Normal fasting-state levels of serum cholyl-conjugated bile acids in Gilbert's syndrome: an aid to the diagnosis. Hepatology 1982; 2:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/44\">",
"      Douglas JG, Beckett GJ, Nimmo IA, et al. Bile salt measurements in Gilbert's syndrome. Eur J Clin Invest 1981; 11:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/45\">",
"      Okolicsanyi L, Fevery J, Billing B, et al. How should mild, isolated unconjugated hyperbilirubinemia be investigated? Semin Liver Dis 1983; 3:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/46\">",
"      Borlak J, Thum T, Landt O, et al. Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert's syndrome) in healthy subjects. Hepatology 2000; 32:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42359/abstract/47\">",
"      Ellis E, Wagner M, Lammert F, et al. Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. J Hepatol 2006; 44:243.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3578 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-4D580CFE0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42359=[""].join("\n");
var outline_f41_23_42359=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BILIRUBIN OVERPRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GILBERT'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Inheritance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Determinants of plasma bilirubin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Specialized tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Alteration in drug metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114101113\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3578\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3578|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/51/31536\" title=\"figure 1\">",
"      Bilirubin in hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/44/33487\" title=\"figure 2\">",
"      UGT gene locus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3578|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/11/27836\" title=\"table 1\">",
"      Inherited uncong hyperbili",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27943?source=related_link\">",
"      Bilirubin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7065?source=related_link\">",
"      Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6201?source=related_link\">",
"      Crigler-Najjar syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/16/3328?source=related_link\">",
"      Patient information: Gilbert's syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/28/21953?source=related_link\">",
"      Patient information: Gilbert&rsquo;s syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_23_42360="Thymic carcinoid high power";
var content_f41_23_42360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59363%7EPULM%2F61672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59363%7EPULM%2F61672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Well-differentiated thymic carcinoid: histologic appearance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Organoid nests composed of uniform polygonal cells with centrally located nuclei and finely granular nuclear chromatin, forming rosettes, are characteristic features of carcinoid tumors. Necrosis is frequently seen in thymic carcinoid. (Hematoxylin and eosin, magnification 100x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Well-differentiated thymic carcinoid: histology showing a mitotic figure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Carcinoid tumors in the thymus often display areas of necrosis and mitotic figures (arrow). (Hematoxylin and eosin, magnification 250x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42360=[""].join("\n");
var outline_f41_23_42360=null;
var title_f41_23_42361="Pathophysiology and genetic features of chronic lymphocytic leukemia";
var content_f41_23_42361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and genetic features of chronic lymphocytic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/23/42361/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/23/42361/contributors\">",
"     Kanti R Rai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/23/42361/contributors\">",
"     Michael J Keating, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/23/42361/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/23/42361/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/23/42361/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/23/42361/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/23/42361/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). According to the current WHO classification, B cell chronic lymphocytic leukemia is considered to be identical (ie, one disease at different stages) to the mature (peripheral) B cell neoplasm small lymphocytic lymphoma (SLL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/1\">",
"     1",
"    </a>",
"    ]. It is characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin.",
"   </p>",
"   <p>",
"    The pathophysiology and molecular biology of B cell",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    will be reviewed here. The incidence, epidemiology, clinical manifestations, diagnosis, and treatment of",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    and its variants (T cell CLL, prolymphocytic leukemia), and the role of bone marrow transplantation are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/6/24680?source=see_link\">",
"     \"Epidemiology and clinical manifestations of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35800?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18887?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4346378\">",
"    <span class=\"h1\">",
"     OVERVIEW OF PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular pathogenesis of CLL is a complex, multistep process leading to the replication of a malignant clone of B-lymphocytes. While some steps in this pathway have been elucidated, many remain unknown. It is believed that virtually all CLL cases are preceded by a premalignant B cell proliferative disorder known as monoclonal B cell lymphocytosis (MBL). MBL with a CLL-phenotype is present in 5 to 15 percent of the population above the age of 60, and progresses to",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    or a related malignancy at a rate of approximately 1 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\", section on 'Monoclonal B-cell lymphocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of CLL can be conceptualized as two sequential processes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establishment of MBL &mdash; While the inciting event is unknown, MBL appears to develop as the result of cytogenetic abnormalities, many of which are thought to be the product of an abnormal response to antigenic stimulation. The result is a clone of memory B cells with a CLL phenotype.",
"     </li>",
"     <li>",
"      Progression from MBL to CLL &mdash; Further insults to the B cell clone, either through additional genetic abnormalities or changes in the bone marrow microenvironment, result in the progression of MBL to CLL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/4\">",
"       4",
"      </a>",
"      ]. This progression occurs in a very minor portion of persons with MBL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CLL tumor cells express B cell antigen receptors (BCRs) with a restricted repertoire of mutations that result in antigen-independent cell-autonomous signalling thought to promote survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/5\">",
"     5",
"    </a>",
"    ]. Once the clonal plasma cell population is created and progresses to CLL, a large subset of patients is asymptomatic. Ultimately, some patients develop signs and symptoms (eg, lymphadenopathy, hepatosplenomegaly, cytopenias, infections) related to the accumulation of functionally incompetent lymphocytes.",
"   </p>",
"   <p>",
"    Complex studies using serial whole-genome sequencing suggest that an individual CLL tumor is genetically heterogeneous, with several subpopulations of malignant cells evolving over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/6\">",
"     6",
"    </a>",
"    ]. The relative contribution of each subpopulation to the total tumor volume is likely affected by interactions with other subpopulations, the tumor microenvironment, and therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMUNOBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially it was felt that the majority of CLL cells were in the G(0) phase of the cell cycle, with less than 1 percent spontaneous mitoses in vitro, suggesting that CLL was a disease of accumulation of long-lived lymphocytes. Indeed, malignant cells accumulate in CLL at least partly due to their inability to undergo apoptosis. Mechanisms of apoptosis resistance in CLL include overexpression of B cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    2 (bcl2) and Fas-inhibitory molecules such as TOSO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/7\">",
"     7",
"    </a>",
"    ]. However, in vivo kinetic studies have uncovered a wide range of cellular proliferation and death rates among individual patients. Those patients with cellular birth rates &gt;0.35",
"    <span class=\"nowrap\">",
"     percent/day",
"    </span>",
"    were much more likely to exhibit active disease or develop progressive disease than those with lower cellular birth rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Morphologically, CLL cells resemble the mature small lymphocytes seen in the peripheral blood of normal individuals. However, CLL lymphocytes are clonal B cells arrested in the B cell differentiation pathway at some intermediate stage between the pre-B cell and mature B cell, perhaps in the \"activated, antigen-experienced\" B cell subset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Phenotype of B-CLL lymphocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three phenotypic features are characteristic of B cell CLL (B-CLL) lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extremely low levels of surface membrane immunoglobulin (often abbreviated as SmIg or sIg). The immunoglobulin is most often IgM or both IgM and IgD, and only rarely IgG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/14\">",
"       14",
"      </a>",
"      ]. Only a single immunoglobulin light chain is expressed (ie, either kappa or lambda).",
"     </li>",
"     <li>",
"      Expression of one or more B cell associated antigens as demonstrated by CD19, CD20, CD21, CD23, and CD24 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Expression of CD5, a T cell associated antigen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/17-19\">",
"       17-19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, variant forms have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/12,20,21\">",
"     12,20,21",
"    </a>",
"    ]. As an example, some cases of CLL are CD11c positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], suggesting an immunophenotypic overlap between CLL and hairy cell leukemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\", section on 'Immunophenotype'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20841?source=see_link\">",
"     \"Clinical features and diagnosis of hairy cell leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Normal counterpart of B-CLL lymphocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have been performed to determine the pathophysiologic implications of the combination of cell surface markers seen in B-CLL. CD5+ B cells (with many or all of the characteristics of B-CLL cells listed above, including monoclonality) can be found in the lymph nodes and spleen of the normal human fetus, and at the edge of germinal centers of lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], as well as in the peripheral blood of normal adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The most frequent B-CLL phenotype corresponds to one or more cellular subsets within the mantle zone of lymph nodes. In addition, approximately 15 percent of normal B cells in the peripheral blood express CD5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CD5 positive B cells are increased in patients with autoimmune disorders, such as rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/30\">",
"     30",
"    </a>",
"    ]. This observation is relevant to CLL, since the pathophysiologic explanation for the increased frequency of Coombs' positivity and other autoimmune phenomena in CLL has remained unresolved. In approximately 25 percent of CLL cases bearing kappa light chains on the lymphocyte surface, the leukemic cells react against an anti-idiotype antibody to a highly conserved region of one specific kappa gene (crossreactive idiotype) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Analysis of kappa gene rearrangement showed considerable sequence homology in the rearranged regions.",
"   </p>",
"   <p>",
"    These observations suggest that specific subsets of CD5+ B cells may be the normal counterparts of B-CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Evaluation of a naturally occurring CD5+ B cell subset that resembled autoantibody-producing B-CLL cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/34\">",
"     34",
"    </a>",
"    ] showed a restricted expression of Ig V genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/34\">",
"     34",
"    </a>",
"    ], raising the possibility that B-CLL may arise from a normal B cell subset engaged in autoantibody production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. A minor subpopulation of normal human CD5+ cells is considered to be a long-lived population circulating between blood and lymph nodes, mostly located in the inner layer of mantle zones; these cells may be the normal counterpart of the neoplastic B-CLL cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     T cells and natural killer cells in CLL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because B cells account for almost 90 percent of all lymphocytes in B-CLL, the percentages of T cells and natural killer (NK) cells are invariably decreased. However, the absolute T cell count is often high, but may be normal or low. In addition, natural killer cells are usually decreased in number as well as function in CLL.",
"   </p>",
"   <p>",
"    Patients with B-CLL also may have an unusual T cell subpopulation expressing lower CD4 or CD8 levels than classic T cells, which may derive from nonclassic pathways of T cell development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/37-40\">",
"     37-40",
"    </a>",
"    ] or through direct interaction with the malignant B cell population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/41\">",
"     41",
"    </a>",
"    ]. Similar cells have been described in human and murine autoimmune disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical consequences of defective B and T cell function in CLL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypogammaglobulinemia is a common finding in CLL and autoimmune disorders occur in up to 25 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/33,42\">",
"     33,42",
"    </a>",
"    ]. Among the autoimmune phenomena are Coombs' positive autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and pure red cell aplasia (PRCA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In one review, AIHA occurred in 11 percent of patients with CLL, primarily in advanced disease, and ITP and PRCA in 2 to 3 and 6 percent, respectively, primarily occurring in early disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/43\">",
"     43",
"    </a>",
"    ]. The autoantibodies appear to be produced by the leukemic clone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to autoimmune disorders, patients with CLL also may have defective antibody responses to specific infections and immunizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/46\">",
"     46",
"    </a>",
"    ]. Infections with gram-negative as well as encapsulated organisms are the most frequent cause of morbidity and mortality in CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. In vitro studies suggest that B-CLL cells may inhibit autologous production of immunoglobulin by interaction with CD95 on normal bone marrow plasma cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CYTOGENETICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;If sensitive tests are used, chromosomal abnormalities can be detected in the majority of patients with CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Whole-genome sequencing of CLL cases and normal paired germ line control material suggests that an average CLL genome contains numerous genetic alterations, many of which are not apparent on standard cytogenetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/53\">",
"     53",
"    </a>",
"    ]. Certain genetic abnormalities have been associated with patient outcomes. Patients with complex genomic changes appear to have more aggressive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/54\">",
"     54",
"    </a>",
"    ]. The most frequently observed abnormalities were trisomy 12 and 14q+. The cytogenetic abnormalities appear to be restricted to B cells in B-CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/55\">",
"     55",
"    </a>",
"    ]. In two studies of patients with CLL using fluorescence in situ hybridization (FISH) techniques, chromosomal abnormalities were noted in 69 to 82 percent, with abnormalities of chromosomes 11, 12, and 13 being most commonly seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of these studies, five categories were defined with a statistical model: 17p deletion, 11q deletion, 12q trisomy, normal karyotype, and 13q deletion as the sole abnormality; median survival times for patients in these five groups were 32, 79, 114, 111, and 133 months, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Karyotypic abnormalities are often acquired over time:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a five-year prospective study of 45 patients with CLL, in whom sequential karyotypic studies were performed every 6 to 12 months, karyotypic evolution occurred in 38 percent and was significantly associated with progressive disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/56\">",
"       56",
"      </a>",
"      ]. Deletions of 11q were the most commonly detected change.",
"     </li>",
"     <li>",
"      In a second prospective sequential study in 159 patients with CLL, the rate of clonal evolution was 1.4 percent during the first two years of follow-up and 27 percent among those tested after five or more years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/57\">",
"       57",
"      </a>",
"      ]. Clonal evolution occurred among 10 versus 42 percent of those who were ZAP-70 negative or positive, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Trisomy 12",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic value of trisomy 12 detected by FISH is not clear. One study using FISH found an association of trisomy 12 with advanced disease and higher proliferative activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/58\">",
"     58",
"    </a>",
"    ], while another study found that median survival in patients with CLL and trisomy 12 detected by FISH was similar to that of patients with CLL and a normal karyotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     del(13q14)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities, most often deletion, of 13q14 were originally noted in up to 20 percent of patients with CLL. However, as with other genetic abnormalities, its frequency is higher with molecular techniques (eg, FISH) than previously reported with conventional techniques (ie, karyotype) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/59\">",
"     59",
"    </a>",
"    ]. In one series of 229 patients, hemizygous (31 percent) and homozygous (10 percent) deletions were noted within 13q14.3, telomeric to the Retinoblastoma (Rb) gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/60\">",
"     60",
"    </a>",
"    ]. Two studies using FISH found del(13q14) in 45 to 55 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/50,61\">",
"     50,61",
"    </a>",
"    ]. These deletions are often associated with inactivation of the Rb gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/60,62\">",
"     60,62",
"    </a>",
"    ]. The region of minimal deletion is suspected to harbor a CLL-associated tumor suppressor gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/63\">",
"     63",
"    </a>",
"    ]; genetic analysis of this region is ongoing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lack of Rb gene expression occurs in both the early and late stages of CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/65\">",
"     65",
"    </a>",
"    ]. When present as the sole abnormalities, monoallelic or biallelic 13q abnormalities appear to be associated with a favorable outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/50,66\">",
"     50,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other deletions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using FISH techniques, deletions of 11q have been described in 17 to 20 percent of patients and deletions of 17p were found in 7 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/50,61\">",
"     50,61",
"    </a>",
"    ]. 11q deletions are the most common type of karyotypic evolution over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing evidence suggests that these abnormalities have prognostic significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      11q deletions are associated with extensive adenopathy, progressive disease and shorter survival, particularly in patients under the age of 55 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/50,61\">",
"       50,61",
"      </a>",
"      ]. Chromosome 11q also contains the ataxia telangiectasia mutated (ATM) gene. Patients who have loss or mutation of both copies of this gene have an even worse overall survival associated with impaired cellular response to irradiation and cytotoxic drug exposure in vitro [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. However, the poor prognosis associated with this abnormality may be overcome with the use of certain chemotherapy regimens such as FCR (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a multivariate analysis of patients with CLL, 17p deletion was the strongest predictor of poor survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/50\">",
"       50",
"      </a>",
"      ]. In addition, several clinical trials have identified 17p deletion as a predictor of poor prognosis among patients requiring therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. However, the prognostic significance of 17p deletion in previously untreated patients is less clear. A retrospective analysis of 99 patients with previously untreated CLL demonstrating a 17p deletion reported heterogeneity in the time to disease progression in this population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/72\">",
"       72",
"      </a>",
"      ]. In this study, approximately half of the patients progressed to requiring therapy in the first 12 to 18 months, while the remaining 50 percent demonstrated relatively stable disease lasting up to six years. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'p53 tumor suppressor gene'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In addition, chromosomal translocations involving the MYC gene located on chromosome 8 at band q24.1, although rare in CLL, are associated with a worse prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MOLECULAR GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in certain genes have been identified in patients with CLL with or without the presence of chromosomal abnormalities. Some of these are discussed below. While these gene mutations have been found to affect tumor suppression genes, oncogenes, DNA damage repair, RNA splicing, and cellular signaling pathways, the prognostic significance of such mutations is not well characterized. However, they are thought to provide insight into the pathobiology of CLL and potential targets for therapy.",
"   </p>",
"   <p>",
"    In one study, massively parallel sequencing was used to compare the coding sequences (exomes) of 91 CLL samples with the coding sequences of matched germline DNA to identify genes with an excessively high somatic mutation rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/74\">",
"     74",
"    </a>",
"    ]. While CLL cells had an average of 20 somatic point mutations identified, nine genes were mutated at a rate significantly higher than the background mutation rate. These nine genes are key components of four major cellular signaling pathways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      DNA damage and cell-cycle control (eg, ATM, p53)",
"     </li>",
"     <li>",
"      Notch signaling (eg, NOTCH1, FBXW7)",
"     </li>",
"     <li>",
"      Inflammatory pathways (eg, MYD88, DDX3X, MAPK1)",
"     </li>",
"     <li>",
"      RNA splicing and processing (eg, SF3B1, DDX3X)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other point mutations were commonly identified, but at a lower mutation rate, within these pathways and within the Wnt signaling pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bcl-2 protooncogene",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was previously suggested that expression of the protooncogene B cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    2 (bcl-2) among hematopoietic malignancies is exclusively observed in follicular lymphomas and in some cases of diffuse large cell lymphomas; in these disorders, there is a t(14;18) chromosomal translocation in which the bcl-2 gene at 18q21 is placed into juxtaposition with the Ig heavy-chain locus at 14q32 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/75\">",
"     75",
"    </a>",
"    ]. However, bcl-2 expression is elevated in approximately 95 percent of patients with B-CLL and to a level similar to t(14;18)-bearing lymphoma cells in 70 percent, via mechanisms other than classic translocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Bcl-2 is expressed in CD5+ B-CLL cells, but not in normal CD5+ B cells. In addition, the expression of Bcl-2 may differ based upon the tumor microenvironment with higher levels seen in CLL cells derived from lymph nodes than in CLL cells derived from the peripheral blood or bone marrow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bcl-2 is unique among proto-oncogenes as a known suppressor of programmed cell death (apoptosis), resulting in prolonged survival of the involved cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/78\">",
"     78",
"    </a>",
"    ]. This observation may provide a molecular explanation for a disease that, in the 1960s, was thought to result from an accumulation of long-lived lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. In vitro studies have shown that B-CLL cells with higher levels of bcl-2 protein survive longer in culture than those with lower levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/75,81\">",
"     75,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another factor that may contribute to prolonged survival of B cell CLL cells is expression of a functional and inducible nitric oxide synthase (iNOS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/82\">",
"     82",
"    </a>",
"    ]. Ligation of CD23, expressed on B-CLL cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], results in increased expression and activity of iNOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/82\">",
"     82",
"    </a>",
"    ]. The nitric oxide produced exerts an antiapoptotic effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     p53 tumor suppressor gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;p53 is a tumor-suppressor gene located on the short arm of chromosome 17; it is inactivated by deletion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    point mutation in many human malignancies. The wild-type p53 gene protein helps trigger apoptosis and acts as a check point regulator of cells entering into S phase. p53 gene mutations have been identified in 10 to 47 percent of patients with CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/74,83-88\">",
"     74,83-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is generally a poorer survival among CLL patients with p53 gene deletion or mutation as compared with those without a deletion or mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/50,70,83,86,87,89,90\">",
"     50,70,83,86,87,89,90",
"    </a>",
"    ]. In one study of 181 patients with B-CLL, for example, expression of p53 (as compared with p53 negative patients) was strongly associated with the presence of p53 gene mutations, a significantly shortened overall survival, and a poorer response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/87\">",
"     87",
"    </a>",
"    ]. In another report, a response to chemotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CHOP",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    occurred in only one of eight patients (13 percent) with p53 mutations compared with 80 percent of 36 patients without such mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/87\">",
"     87",
"    </a>",
"    ]. In this regard, gene expression studies have suggested that treatment of CLL patients with fludarabine has the potential to select for induction of p53 mutant subclones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78366082\">",
"    <span class=\"h2\">",
"     Notch1 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Notch proteins are transmembrane receptors that are involved in regulating hematopoietic cell development. Mutations in Notch can be found in a subset of patients with lymphoproliferative disorders, such as CLL. A whole-genome sequencing study that compared samples from four patients with CLL and normal paired germ line control material identified recurrent somatic mutations in NOTCH1, XPO1, MYC88, and KLHL6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/53\">",
"     53",
"    </a>",
"    ]. Analysis in larger cohorts identified NOTCH1 mutations in 4 to 12 percent of CLL patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/53,74,92-95\">",
"     53,74,92-95",
"    </a>",
"    ]. NOTCH1 mutations were associated with unmutated immunoglobulin variable heavy chain genes and a poor clinical outcome.",
"   </p>",
"   <p>",
"    The prognostic impact of NOTCH1 mutations was evaluated in 466 patients with previously untreated CLL enrolled on the UK LRF CLL4 randomized trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    with and without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as first line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/95\">",
"     95",
"    </a>",
"    ]. NOTCH1 mutations were identified in 10 percent of patients and correlated with other markers of poor prognosis (ie, unmutated immunoglobulin Vh genes, CD38 positivity, ZAP-70 expression). NOTCH1 mutations were associated with decreased progression-free (median 22 versus 26 months) and overall (median 55 versus 75 months) survival. Following multivariate analysis, NOTCH1 mutation was an independent predictor of poor overall survival (hazard ratio 1.58; 95% CI 1.05-2.38).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14703943\">",
"    <span class=\"h2\">",
"     SF3B1 gene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SF3B1 gene encodes for part of a nuclear ribonucleoprotein that complexes with other nuclear ribonucleoproteins to create the spliceosome that is responsible for splicing messenger RNA. SF3B1 mutations can be identified in a subset of patients with CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/74,95-98\">",
"     74,95-98",
"    </a>",
"    ]. As an example, recurrent somatic point mutations (most commonly K700E) were seen in 14 of 91 patients (15 percent) with CLL in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/74,99\">",
"     74,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among 437 patients with previously untreated CLL enrolled on the UK LRF CLL4 trial, SF3B1 gene mutations were identified in 17 percent and were associated with high CD38 expression and decreased survival (median 54 versus 79 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/95\">",
"     95",
"    </a>",
"    ]. Following multivariate analysis, SF3B1 gene mutations were an independent predictor of poor overall survival (hazard ratio 1.52; 95% CI 1.10-2.12).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     MicroRNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;MicroRNAs (miRNAs) are a novel class of small noncoding RNAs that modulate the expression of genes at the post-transcriptional level, and are involved in cancer, apoptosis, and cell metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/100\">",
"     100",
"    </a>",
"    ]. They may have particular relevance to CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15466?source=see_link&amp;anchor=H16#H16\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\", section on 'Other markers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations in miRNA transcripts are frequent, some of them germ-line, and may predispose to CLL and to a spectrum of associated malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/103-105\">",
"       103-105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 56 patients with CLL, marked overexpression of two microRNAs (miR-21 and miR-155) was seen in almost every sample analyzed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MicroRNA-15a and miR-16-1 have been shown to interact directly with and result in the upregulation of the B cell",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma",
"      </span>",
"      2 (BCL2) antiapoptotic protein in many cases of CLL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/107\">",
"       107",
"      </a>",
"      ]. These two mRNAs are not present in CLL with 13q deletion, a genetic finding associated with a favorable outcome. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'del(13q14)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Bcl-2 protooncogene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The expression of microRNA may be regulated by tumor suppressor genes or through epigenetic modification. As an example, the expression of a microRNA cluster located at 11q",
"      <span class=\"nowrap\">",
"       (miR34b/miR-34c)",
"      </span>",
"      appears to be directly activated by TP53 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/108\">",
"       108",
"      </a>",
"      ]. In contrast, increased histone deacetylase activity appears to downregulate the expression of other microRNAs (eg, miR15a, miR16, miR29b), resulting in decreased apoptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/109\">",
"       109",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'p53 tumor suppressor gene'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unknown how microRNA and other regulatory systems interact to produce CLL",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    determine its aggressiveness. One proposal is that there is a complex interaction between",
"    <span class=\"nowrap\">",
"     miR-15a/miR-16-1,",
"    </span>",
"    <span class=\"nowrap\">",
"     miR-34b/miR-34c,",
"    </span>",
"    BCL2, ZAP70, and TP53 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42361/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/10/6309?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6814180\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin. According to the current WHO classification, CLL is considered to be identical (ie, one disease at different stages) to the mature (peripheral) B cell neoplasm small lymphocytic lymphoma.",
"     </li>",
"     <li>",
"      The molecular pathogenesis of CLL is a complex, multistep process leading to the replication of a malignant clone of B cell origin. While some steps in this pathway have been elucidated, many remain unknown. (See",
"      <a class=\"local\" href=\"#H4346378\">",
"       'Overview of pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Morphologically, CLL cells resemble the mature small lymphocytes seen in the peripheral blood of normal individuals. However, CLL lymphocytes are clonal B cells arrested in the B cell differentiation pathway at some intermediate stage between the pre-B cell and mature B cell, perhaps in the \"activated, antigen-experienced\" B cell subset. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Immunobiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If sensitive tests are used, chromosomal abnormalities can be detected in the majority of patients with CLL. Certain genetic abnormalities have been associated with patient outcomes. Patients with complex genomic changes appear to have more aggressive disease, while 13q deletion is associated with a favorable outcome. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cytogenetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of cases of CLL demonstrate increased expression of B cell",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma",
"      </span>",
"      2 (BCL2), a proto-oncogene that suppresses programmed cell death (apoptosis). In addition, a minority of patients demonstrate deletions of the p53 tumor suppressor gene located on the short arm of chromosome 17. The wild-type p53 gene protein helps trigger apoptosis while its deletion allows for cell survival. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Molecular genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MicroRNAs (miRNAs) are a novel class of small, noncoding RNAs that modulate the expression of genes at the post-transcriptional level, and are involved in cancer, apoptosis, and cell metabolism. They appear to interact with BCL2 and p53 in CLL and may be important in the pathogenesis of this disorder. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'MicroRNA'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/2\">",
"      Rossi D, Sozzi E, Puma A, et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol 2009; 146:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/3\">",
"      Shanafelt TD, Kay NE, Rabe KG, et al. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol 2009; 27:3959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/4\">",
"      Ghia P, Caligaris-Cappio F. Monoclonal B-cell lymphocytosis: right track or red herring? Blood 2012; 119:4358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/5\">",
"      D&uuml;hren-von Minden M, &Uuml;belhart R, Schneider D, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012; 489:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/6\">",
"      Wu CJ. CLL clonal heterogeneity: an ecology of competing subpopulations. Blood 2012; 120:4117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/7\">",
"      Pallasch CP, Schulz A, Kutsch N, et al. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood 2008; 112:4213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/8\">",
"      Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/9\">",
"      Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/10\">",
"      Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002; 99:4087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/11\">",
"      Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004; 103:4389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/12\">",
"      Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87:4990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/13\">",
"      Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/14\">",
"      Potter KN, Mockridge CI, Neville L, et al. Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia. Clin Cancer Res 2006; 12:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/15\">",
"      Geisler CH, Larsen JK, Hansen NE, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 1991; 78:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/16\">",
"      Fournier S, Delespesse G, Rubio M, et al. CD23 antigen regulation and signaling in chronic lymphocytic leukemia. J Clin Invest 1992; 89:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/17\">",
"      Boumsell L, Coppin H, Pham D, et al. An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells. Distribution on normal and malignant lymphoid cells. J Exp Med 1980; 152:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/18\">",
"      Freedman AS, Boyd AW, Bieber FR, et al. Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood 1987; 70:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/19\">",
"      Freedman AS. Immunobiology of chronic lymphocytic leukemia. Hematol Oncol Clin North Am 1990; 4:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/20\">",
"      Kurec AS, Threatte GA, Gottlieb AJ, et al. Immunophenotypic subclassification of chronic lymphocytic leukaemia (CLL). Br J Haematol 1992; 81:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/21\">",
"      Royston I, Majda JA, Baird SM, et al. Human T cell antigens defined by monoclonal antibodies: the 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. J Immunol 1980; 125:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/22\">",
"      Hanson CA, Gribbin TE, Schnitzer B, et al. CD11c (LEU-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia. Blood 1990; 76:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/23\">",
"      Wormsley SB, Baird SM, Gadol N, et al. Characteristics of CD11c+CD5+ chronic B-cell leukemias and the identification of novel peripheral blood B-cell subsets with chronic lymphoid leukemia immunophenotypes. Blood 1990; 76:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/24\">",
"      Antin JH, Emerson SG, Martin P, et al. Leu-1+ (CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: phenotypic and functional studies. J Immunol 1986; 136:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/25\">",
"      Bofill M, Janossy G, Janossa M, et al. Human B cell development. II. Subpopulations in the human fetus. J Immunol 1985; 134:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/26\">",
"      Caligaris-Cappio F, Gobbi M, Bofill M, Janossy G. Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med 1982; 155:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/27\">",
"      Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of \"indolent\" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002; 100:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/28\">",
"      Ghia P, Prato G, Scielzo C, et al. Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 2004; 103:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/29\">",
"      Gadol N, Ault KA. Phenotypic and functional characterization of human Leu1 (CD5) B cells. Immunol Rev 1986; 93:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/30\">",
"      Plater-Zyberk C, Maini RN, Lam K, et al. A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis Rheum 1985; 28:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/31\">",
"      Kipps TJ, Tomhave E, Chen PP, Carson DA. Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy. J Exp Med 1988; 167:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/32\">",
"      Kipps TJ, Tomhave E, Pratt LF, et al. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 1989; 86:5913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/33\">",
"      Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993; 81:2475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/34\">",
"      Inghirami G, Foitl DR, Sabichi A, et al. Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression. Blood 1991; 78:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/35\">",
"      Dighiero G. Biology of the neoplastic lymphocyte in B-CLL. Baillieres Clin Haematol 1993; 6:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/36\">",
"      Abe M, Tominaga K, Wakasa H. Phenotypic characterization of human B-lymphocyte subpopulations, particularly human CD5+ B-lymphocyte subpopulation within the mantle zones of secondary follicles. Leukemia 1994; 8:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/37\">",
"      Dianzani U, Omed&egrave; P, Marmont F, et al. Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype. Blood 1994; 83:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/38\">",
"      Scrivener S, Kaminski ER, Demaine A, Prentice AG. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br J Haematol 2001; 112:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/39\">",
"      Christopoulos P, Pfeifer D, Bartholom&eacute; K, et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 2011; 117:3836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/40\">",
"      Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013; 121:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/41\">",
"      G&ouml;rg&uuml;n G, Holderried TA, Zahrieh D, et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005; 115:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/42\">",
"      Dighiero G. An attempt to explain disordered immunity and hypogammaglobulinemia in B-CLL. Nouv Rev Fr Hematol 1988; 30:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/43\">",
"      Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/44\">",
"      Majumdar G, Brown S, Slater NG, Singh AK. Clinical spectrum of autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Leuk Lymphoma 1993; 9:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/45\">",
"      Sthoeger ZM, Sthoeger D, Shtalrid M, et al. Mechanism of autoimmune hemolytic anemia in chronic lymphocytic leukemia. Am J Hematol 1993; 43:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/46\">",
"      Sinisalo M, Aittoniemi J, Oivanen P, et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol 2001; 114:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/47\">",
"      Molica S. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leuk Lymphoma 1994; 13:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/48\">",
"      Salonen J, Nikoskelainen J. Lethal infections in patients with hematological malignancies. Eur J Haematol 1993; 51:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/49\">",
"      Sampalo A, Navas G, Medina F, et al. Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction. Blood 2000; 96:3168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/50\">",
"      D&ouml;hner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/51\">",
"      Reddy KS. Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel. Br J Haematol 2006; 132:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/52\">",
"      Grubor V, Krasnitz A, Troge JE, et al. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood 2009; 113:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/53\">",
"      Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/54\">",
"      Kujawski L, Ouillette P, Erba H, et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood 2008; 112:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/55\">",
"      Knuutila S, Elonen E, Teerenhovi L, et al. Trisomy 12 in B cells of patients with B-cell chronic lymphocytic leukemia. N Engl J Med 1986; 314:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/56\">",
"      Fegan C, Robinson H, Thompson P, et al. Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995; 9:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/57\">",
"      Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006; 24:4634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/58\">",
"      Garc&igrave;a-Marco JA, Price CM, Ellis J, et al. Correlation of trisomy 12 with proliferating cells by combined immunocytochemistry and fluorescence in situ hybridization in chronic lymphocytic leukemia. Leukemia 1996; 10:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/59\">",
"      Lehmann S, Ogawa S, Raynaud SD, et al. Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia. Cancer 2008; 112:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/60\">",
"      Corcoran MM, Rasool O, Liu Y, et al. Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia. Blood 1998; 91:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/61\">",
"      D&ouml;hner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997; 89:2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/62\">",
"      Liu Y, Grand&eacute;r D, S&ouml;derh&auml;ll S, et al. Retinoblastoma gene deletions in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 1992; 4:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/63\">",
"      Kalachikov S, Migliazza A, Cayanis E, et al. Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics 1997; 42:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/64\">",
"      Migliazza A, Bosch F, Komatsu H, et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001; 97:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/65\">",
"      Neubauer A, de Kant E, Rochlitz C, et al. Altered expression of the retinoblastoma susceptibility gene in chronic lymphocytic leukaemia. Br J Haematol 1993; 85:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/66\">",
"      Garg R, Wierda W, Ferrajoli A, et al. The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer 2012; 118:3531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/67\">",
"      Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007; 25:5448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/68\">",
"      Skowronska A, Parker A, Ahmed G, et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol 2012; 30:4524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/69\">",
"      Tsimberidou AM, Tam C, Abruzzo LV, et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009; 115:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/70\">",
"      Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010; 28:4473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/71\">",
"      Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011; 29:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/72\">",
"      Tam CS, Shanafelt TD, Wierda WG, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009; 114:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/73\">",
"      Huh YO, Lin KI, Vega F, et al. MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol 2008; 142:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/74\">",
"      Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365:2497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/75\">",
"      Hanada M, Delia D, Aiello A, et al. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/76\">",
"      Papakonstantinou G, Verbeke C, Hastka J, et al. bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements. Br J Haematol 2001; 113:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/77\">",
"      Herishanu Y, P&eacute;rez-Gal&aacute;n P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/78\">",
"      Hockenbery D, Nu&ntilde;ez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/79\">",
"      Galton DA. The pathogenesis of chronic lymphocytic leukemia. Can Med Assoc J 1966; 94:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/80\">",
"      Dameshek W. Chronic lymphocytic leukemia--an accumulative disease of immunolgically incompetent lymphocytes. Blood 1967; 29:Suppl:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/81\">",
"      Ricciardi MR, Petrucci MT, Gregorj C, et al. Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. Br J Haematol 2001; 113:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/82\">",
"      Zhao H, Dugas N, Mathiot C, et al. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 1998; 92:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/83\">",
"      D&ouml;hner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/84\">",
"      el Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82:3452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/85\">",
"      Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 1991; 88:5413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/86\">",
"      Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84:3148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/87\">",
"      Cordone I, Masi S, Mauro FR, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998; 91:4342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/88\">",
"      Barnabas N, Shurafa M, Van Dyke DL, et al. Significance of p53 mutations in patients with chronic lymphocytic leukemia: a sequential study of 30 patients. Cancer 2001; 91:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/89\">",
"      Zenz T, Kr&ouml;ber A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112:3322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/90\">",
"      Trbusek M, Smardova J, Malcikova J, et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011; 29:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/91\">",
"      Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004; 104:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/92\">",
"      Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/93\">",
"      Balatti V, Bottoni A, Palamarchuk A, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012; 119:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/94\">",
"      Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/95\">",
"      Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013; 121:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/96\">",
"      Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011; 118:6904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/97\">",
"      Hahn CN, Scott HS. Spliceosome mutations in hematopoietic malignancies. Nat Genet 2012; 44:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/98\">",
"      Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012; 44:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/99\">",
"      Mori J, Takahashi Y, Tanimoto T. SF3B1 in chronic lymphocytic leukemia. N Engl J Med 2012; 366:1057; author reply 1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/100\">",
"      Lawrie CH. MicroRNAs and haematology: small molecules, big function. Br J Haematol 2007; 137:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/101\">",
"      Calin GA, Croce CM. Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood 2009; 114:4761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/102\">",
"      Visone R, Rassenti LZ, Veronese A, et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009; 114:3872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/103\">",
"      Calin GA, Croce CM. Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Semin Oncol 2006; 33:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/104\">",
"      Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/105\">",
"      Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004; 101:11755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/106\">",
"      Fulci V, Chiaretti S, Goldoni M, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007; 109:4944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/107\">",
"      Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99:15524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/108\">",
"      Corney DC, Flesken-Nikitin A, Godwin AK, et al. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007; 67:8433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/109\">",
"      Sampath D, Liu C, Vasan K, et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012; 119:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42361/abstract/110\">",
"      Fabbri M, Bottoni A, Shimizu M, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011; 305:59.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4539 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42361=[""].join("\n");
var outline_f41_23_42361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6814180\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4346378\">",
"      OVERVIEW OF PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMUNOBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Phenotype of B-CLL lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Normal counterpart of B-CLL lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      T cells and natural killer cells in CLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical consequences of defective B and T cell function in CLL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CYTOGENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Trisomy 12",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      del(13q14)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other deletions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MOLECULAR GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bcl-2 protooncogene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      p53 tumor suppressor gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H78366082\">",
"      Notch1 mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14703943\">",
"      SF3B1 gene mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MicroRNA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6814180\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20841?source=related_link\">",
"      Clinical features and diagnosis of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18887?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/6/24680?source=related_link\">",
"      Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35800?source=related_link\">",
"      Hematopoietic cell transplantation in chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/10/6309?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15466?source=related_link\">",
"      Staging and prognosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_23_42362="Enterotoxicity of chemotherapeutic agents";
var content_f41_23_42362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Enterotoxicity of chemotherapeutic agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/23/42362/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/23/42362/contributors\">",
"     Smitha S Krishnamurthi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/23/42362/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/23/42362/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/23/42362/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/23/42362/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/23/42362/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal (GI) toxicity due to chemotherapeutic drugs is a common problem in cancer patients. The specific chemotherapy-related GI complications that are reviewed here include diarrhea, constipation, colitis (neutropenic, C. difficile-induced, and immune-mediated), and intestinal perforation. Chemotherapy-induced oral toxicity (mucositis), and nausea and vomiting are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38250?source=see_link\">",
"     \"Oral toxicity associated with chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39894?source=see_link\">",
"     \"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIARRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy-induced diarrhea (CID) is most commonly described with fluoropyrimidines (particularly 5-fluorouracil [5-FU] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    . Diarrhea is the dose-limiting and major toxicity of regimens containing a fluoropyrimidine with or without irinotecan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    cause acute damage to the intestinal mucosa, leading to loss of epithelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. 5-FU induces mitotic arrest of crypt cells, leading to an increase in the ratio of immature secretory crypt cells to mature villous enterocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. The increased volume of fluid that leaves the small bowel exceeds the absorptive capacity of the colon, leading to clinically significant diarrhea.",
"   </p>",
"   <p>",
"    With",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , early onset diarrhea occurs during or within several hours of drug infusion in 45 to 50 percent of patients and is cholinergically mediated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/4\">",
"     4",
"    </a>",
"    ]. This effect is thought to be due to structural similarity of the drug with acetylcholine. In contrast, late irinotecan-associated diarrhea is not cholinergically mediated. The pathophysiology of late diarrhea appears to be multifactorial with contributions from dysmotility and secretory factors as well as a direct toxic effect on the intestinal mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     Irinotecan",
"    </a>",
"    produces mucosal changes associated with apoptosis, such as epithelial vacuolization, and goblet cell hyperplasia, suggestive of mucin hypersecretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/2\">",
"     2",
"    </a>",
"    ]. These changes appear related to the accumulation of the active metabolite of irinotecan, SN-38, in the intestinal mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SN-38 is glucuronidated in the liver and is then excreted in the bile. The conjugated metabolite SN-38G does not appear to cause diarrhea. However, SN-38G can be deconjugated in the intestines by beta-glucuronidase present in intestinal bacteria. A direct correlation has been noted between mucosal damage and either low glucuronidation rates or increased intestinal beta-glucuronidase activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Severe toxicity has been described with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    in patients with Gilbert's syndrome who have defective hepatic glucuronidation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/9\">",
"     9",
"    </a>",
"    ]. On the other hand, experimental studies have shown that inhibition of intestinal beta-glucuronidase activity with antibiotics protects against mucosal injury and ameliorates the diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H18#H18\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Irinotecan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common genetic polymorphisms of the UDP-glucuronyltransferase gene can affect the metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    . The possible impact of genetic variability on the toxicity of irinotecan is discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Irinotecan plus 5-FU'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;CID can be debilitating and in some cases, life-threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders such as hypokalemia, metabolic acidosis, and depending upon water intake, hyponatremia (increased water intake that cannot be excreted because of the hypovolemic stimulus to the release of antidiuretic hormone) or hypernatremia (insufficient water intake to replace losses). CID can also lead to treatment delays, increased cost of care, reduced quality of life, and diminished compliance with treatment regimens.",
"   </p>",
"   <p>",
"    The severity of CID is often described using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grades; the latest version (v4.03) is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef65649 \" href=\"mobipreview.htm?22/60/23499\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/11\">",
"     11",
"    </a>",
"    ]. Severity is determined by the number of stools per day or increase in ostomy output compared to baseline, the need for hospitalization, and effect on activities of self-care. It is critical to ascertain the patient&rsquo;s baseline bowel pattern when grading the severity of diarrhea. Although adequate for study purposes, these criteria have been criticized because they do not take into account the volume or the duration of diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/3\">",
"     3",
"    </a>",
"    ]. Other validated diarrhea measurement scales have been developed but are not in general use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1730603\">",
"    <span class=\"h2\">",
"     Specific drugs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     5-Fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoropyrimidines such as 5-FU (and its oral derivatives",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , and UFT, see below) cause diarrhea. Both the therapeutic efficacy and frequency of diarrhea associated with 5-FU are increased when given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (LV). The highest frequency of diarrhea occurs with bolus rather than continuous 24-hour infusion of",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    for up to five days, particularly with weekly administration, but it occurs with all schedules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H10#H10\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Leucovorin plus 5-FU'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H4#H4\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on '5-FU-based therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In multiple reports of weekly",
"    <span class=\"nowrap\">",
"     5-FU/LV,",
"    </span>",
"    diarrhea has been seen in up to 50 percent of patients, one-half of whom required hospitalization for intravenous fluids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/13,14,17\">",
"     13,14,17",
"    </a>",
"    ]. In one series, 11 of 221 patients (5 percent) died of treatment-related toxicity, most of them elderly patients with concomitant leukopenia and sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, treatment is routinely withheld for &gt; grade 2 diarrhea, an approach that has led to a significant reduction in severe enterotoxicity with these regimens. No risk factor can reliably predict the development of diarrhea with 5-FU therapy, but the risk is increased in the presence of an unresected primary tumor, shortened bowel resulting from pervious surgery, previous episodes of CID, treatment during the summer season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/19\">",
"     19",
"    </a>",
"    ], and when bolus 5-FU and LV are combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women appear to suffer more toxicity from 5-FU than men, for unclear reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In a meta-analysis of over 2400 patients enrolled in five trials (three for advanced disease, two in the adjuvant setting), significantly more women experienced &ge; grade 3 toxicity during therapy than did men (50 versus 40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/21\">",
"     21",
"    </a>",
"    ]. All of these trials used a five-day bolus schedule of 5-FU and LV. These data suggest that women may be better served by less toxic administration schedules of 5-FU, including short-term infusional regimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H10#H10\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Leucovorin plus 5-FU'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Predictive markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because early detection of patients who are at risk of developing life-threatening toxicity to 5-FU might allow dose reduction or selection of an alternative treatment regimen, various genotypic and phenotypic approaches have been undertaken to predict toxicity. None has proven to be sufficiently reliable to be adopted in routine clinical care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H717960356\">",
"    <span class=\"h5\">",
"     DPD deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dihydropyrimidine dehydrogenase (DPD), the first of three enzymes in the fluoropyrimidine metabolic pathway, is the rate limiting enzyme in 5-FU catabolism. Enzyme activity varies widely, with most of the variability arising from genetic polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) gene. Patients who are partially or totally deficient in DPD activity cannot adequately degrade fluoropyrimidines, leading to an increased risk of severe, sometimes fatal toxicity. In patients with even partial DPD deficiency, administration of a fluoropyrimidine can lead to life-threatening complications, including severe diarrhea, mucositis, and pancytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/23-31\">",
"     23-31",
"    </a>",
"    ]. Nausea, vomiting, rectal bleeding, volume depletion, skin changes, and neurologic abnormalities (cerebellar ataxia, cognitive dysfunction, altered level of consciousness) may also occur.",
"   </p>",
"   <p>",
"    Although complete DPD deficiency is rare, reduced levels of enzyme activity are more common, particularly in blacks and women. These demographic differences were illustrated in an analysis of enzyme levels from 258 normal volunteers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/32\">",
"     32",
"    </a>",
"    ]. Partial DPD deficiency was present in 12.3, 4.0, 3.5, and 1.9 percent of black women and men, and white women and men, respectively.",
"   </p>",
"   <p>",
"    Molecular analysis of patients with DPD deficiency has identified over 40 mutations and polymorphisms in the DPYD gene that may result in partial or total loss of DPD activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. A few alleles are associated with a marked decrease in DPD activity and enhanced fluoropyrimidine toxicity, the most important of which is DPYD *2A (splice site variant 1905+1G&gt;A, also called IVS14+1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/33,35-41\">",
"     33,35-41",
"    </a>",
"    ]. In one series, one of three variants (DYPD *2A, DYPD *9B [also known as D949V], or DPYD *13 [also known as 1679T&gt;G, and I560S]) were found in 30 percent of 5-FU-treated patients (13 of 44) who developed grade 3 or 4 toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/33\">",
"     33",
"    </a>",
"    ]. The authors concluded that patients who inherit high-risk DPYD variants have a sevenfold increased risk of severe toxicity with 5-FU. &nbsp;",
"   </p>",
"   <p>",
"    However, others have found that the DPYD *2A allele is present in fewer than 10 percent of patients with severe 5-FU toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/37,42\">",
"     37,42",
"    </a>",
"    ]. In one of these studies, a prospective study of 683 patients receiving 5-FU monotherapy, genotyping revealed the DPYD*2A allele in only 5 percent of those with treatment-related toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/37\">",
"     37",
"    </a>",
"    ]. Furthermore, fewer than one-half of those who had the DPYD *2A allele had grade 3 or 4 toxicity (positive predictive value 46 percent). For unclear reasons, the presence of DPYD*2A was a stronger predictive factor for severe toxicity in men than in women.",
"   </p>",
"   <p>",
"    Another issue is that inheritance of one of these alleles does not account for all cases of DPD deficiency. Impaired DPD activity has been detected in some patients with normal levels of wild-type DPYD, presumably due to epigenetic mechanisms that regulate enzyme activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To avoid the risk of severe and potentially fatal reactions, the manufacturers of both 5-FU and the oral fluoropyrimidine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    recommend that the drugs are contraindicated in patients with known DPD deficiency. However, preemptive genetic testing of all patients due to receive a fluoropyrimidine in order to identify those with DPD deficiency is controversial and not widely practiced. (See",
"    <a class=\"local\" href=\"#H44530323\">",
"     'Pharmacogenetic testing for DPYD and TYMS variants'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44530683\">",
"    <span class=\"h5\">",
"     TYMS gene variations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thymidylate synthetase (TS), a critical enzyme for thymidine production, is potently inhibited by 5-FU. The 5-FU metabolite, 5-FdUMP, forms a stable complex with TS and folate, blocking the activity of this enzyme. Expression of the TS gene (TYMS) is regulated by transcription factors that bind to the promoter region, a section of coding sequence that lies upstream from the gene. The promoter region of TYMS contains polymorphisms for a double [2R] or triple [3R] repeat that affects TS levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Patients who are homozygous for the triple repeat",
"    <span class=\"nowrap\">",
"     (3R/3R)",
"    </span>",
"    have a greater number of binding sites for transcription factor and higher TS levels, compared to those who are",
"    <span class=\"nowrap\">",
"     2R/2R",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     3R/2R;",
"    </span>",
"    conversely,",
"    <span class=\"nowrap\">",
"     2R/2R",
"    </span>",
"    homozygotes have low TS levels in normal tissues and may be at a greater risk of 5-FU cytotoxicity.",
"   </p>",
"   <p>",
"    Three studies have examined a total of 200 unselected patients who received 5-FU, 44 (22 percent) of whom developed grade 3 or 4 toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Of the 25 patients with the",
"    <span class=\"nowrap\">",
"     2R/2R",
"    </span>",
"    high-risk genotype, 13 (52 percent) had grade 3 or 4 toxicity. Taken together, these data suggest that TYMS polymorphisms are associated with a 1.4 to 2.4-fold increase in the risk of severe toxicity from 5-FU-based chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44530527\">",
"    <span class=\"h5\">",
"     Other markers of 5-FU toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiencies have also been reported in other catabolic enzymes (dihydropyrimidinase, and beta-ureidopropionase) that impair the uracil catabolic pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Their contribution to 5-FU toxicity is not well characterized.",
"   </p>",
"   <p>",
"    The contribution of other genetic and nongenetic factors has not been well studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least some data suggest marked regional differences in tolerability of fluoropyrimidines, with the highest toxicity rates in the US and the lowest in east Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/52\">",
"     52",
"    </a>",
"    ]. This may be due, in part, to differences in dietary folinic acid intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Reduced folates (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) stabilize the binding of the 5-FU metabolite fluorodeoxyuridine monophosphate to thymidylate synthase, enhancing the response to fluoropyrimidine therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/54\">",
"     54",
"    </a>",
"    ], but also increasing toxicity. Higher pretreatment serum folate levels have also been linked to greater toxicity from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , an orally active prodrug of 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Capecitabine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A model combining genetic and nongenetic factors has been developed that predicted severe enterotoxicity in patients who were mostly treated with 5-FU monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/37\">",
"     37",
"    </a>",
"    ]. The model was criticized for its lack of comprehensiveness, the diverse group of patients studied, and the use of 5-FU monotherapy, which is uncommonly used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44530323\">",
"    <span class=\"h4\">",
"     Pharmacogenetic testing for DPYD and TYMS variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacogenetic profiling has the potential to identify patients who may experience severe adverse effects with 5-FU-based regimens. &nbsp;",
"   </p>",
"   <p>",
"    Diagnosis of DPD deficiency can be made by radioimmunometric assay for the DPD enzyme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/56\">",
"     56",
"    </a>",
"    ] or by sequencing of the DPYD gene from a sample of peripheral blood (TheraGuide 5-FU) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/57\">",
"     57",
"    </a>",
"    ], but neither provides rapid results. A simple uracil breath test has been developed to detect abnormalities in the entire catabolic pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/58\">",
"     58",
"    </a>",
"    ], but is not yet commercially available.",
"   </p>",
"   <p>",
"    TheraGuide 5-FU (Myriad laboratories) is a commercially available test that analyzes DNA from peripheral blood cells to fully sequence the DPYD gene (for the three most common DYPD polymorphisms and other rare variants) and detect TYMS variants that increase risk for 5-FU toxicity. It costs $1000, and turnaround time is seven days from the day of receipt of the sample. Test results classify patients as high, moderate, or low-risk, or indeterminant (",
"    <a class=\"graphic graphic_table graphicRef63572 \" href=\"mobipreview.htm?0/36/588\">",
"     table 2",
"    </a>",
"    ). Patients classified as indeterminant may have other polymorphisms for which the risk of 5-FU toxicity is not yet defined.",
"   </p>",
"   <p>",
"    Testing with TheraGuide 5-FU is indicated in any patient experiencing severe toxicity after receiving a fluoropyrimidine-containing regimen. Some authors suggest that testing should ideally be carried out before initiation of treatment to identify those patients at high risk of toxicity with 5-FU or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. However, this is a controversial area, and this approach has not been widely adopted. Although there are some uncontrolled data suggesting lower toxicity and preserved antitumor efficacy when 5-FU doses were empirically adjusted based upon serum ratio of uracil to dihydrouracil",
"    <span class=\"nowrap\">",
"     (U/UH2,",
"    </span>",
"    a surrogate for DPD enzyme activity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/31\">",
"     31",
"    </a>",
"    ], there are no prospective randomized trials which demonstrate improved toxicity without compromise of efficacy in patients who are preemptively screened using any assay for DPD activity, including TheraGuide 5-FU. Furthermore, there are no accepted guidelines for management of patients who are identified as having a high or moderate risk for toxicity according to the assay (ie, should they receive a lower initial dose, enhanced surveillance, pharmacokinetic monitoring, an alternate agent, or a more informed discussion regarding risk).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H204886729\">",
"    <span class=\"h4\">",
"     Management of DPD-deficient patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a DPYD variant is identified prior to treatment, options include use of an alternative agent. As an example, the quinazoline folate analog",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/1/21525?source=see_link\">",
"     raltitrexed",
"    </a>",
"    , which is a thymidylate synthase inhibitor, may be a useful substitute for 5-FU in patients with DPD deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/61\">",
"     61",
"    </a>",
"    ], but it is not available in the US. Tegafur-uracil (UFT) is not a safe substitute for 5-FU in this situation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/62\">",
"     62",
"    </a>",
"    ] as it is a combination of tegafur, a 5-FU pro-drug, plus uracil, which competes with 5-FU for DPD.",
"   </p>",
"   <p>",
"    Where available, another option is close monitoring of 5-FU levels and pharmacokinetically-guided dosing. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pharmacokinetically-guided dosing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most cases of DPD deficiency are diagnosed only after a severe reaction to 5-FU. Management of these patients should include aggressive hemodynamic support, parenteral nutrition, antibiotics, and hematopoietic colony stimulating factors. Dialysis is of no benefit if renal function is normal since, even with complete DPYD deficiency, 5-FU is rapidly cleared through the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H204886589\">",
"    <span class=\"h5\">",
"     Uridine triacetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/25/44433?source=see_link\">",
"     Uridine triacetate",
"    </a>",
"    (originally called",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/25/44433?source=see_link\">",
"     vistonuridine",
"    </a>",
"    ) is an orally administered prodrug of uridine, a specific pharmacologic antidote to 5-FU. It is a safe, effective, and potentially life-saving treatment for 5-FU overdose. In a preliminary report, all 28 cases treated with uridine triacetate for 5-FU overexposure (10 g every six hours for 20 doses, starting within 8 to 96 hours of the 5-FU dose) recovered, compared to 4 of 43 who did not receive it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/63\">",
"     63",
"    </a>",
"    ]. Uridine triacetate is not commercially available, but it has received orphan drug designation for treatment of 5-FU overexposure from both the US FDA and the European Medicines Agency.",
"   </p>",
"   <p>",
"    There are no data on the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/25/44433?source=see_link\">",
"     uridine triacetate",
"    </a>",
"    in patients who develop severe 5-FU toxicity because of DPD deficiency, and this is not an approved indication. However, the drug prevents fatalities in mice who are treated with FU after receiving an inhibitor of DPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/64\">",
"     64",
"    </a>",
"    ]. Thus, DPD-deficient patients who have received FU should also benefit from treatment with uridine triacetate if the deficiency is identified soon enough after 5-FU dosing, and the drug can be obtained within 96 hours of the 5-FU dose.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/25/44433?source=see_link\">",
"     Uridine triacetate",
"    </a>",
"    is available from its manufacturer, Wellstat Therapeutics, under an emergency-use Investigational New Drug (IND) waiver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/65\">",
"     65",
"    </a>",
"    ]. Release of the drug is decided on a case by case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Pharmacokinetically-guided dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like most other cytotoxic drugs, dosing of 5-FU is based upon body surface area (BSA). However, a complete lack of association between BSA and 5-FU clearance has been shown by two independent groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Pharmacokinetically-guided dosing might improve the therapeutic index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This issue was addressed in a trial in which 208 patients with metastatic colorectal cancer received 1500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    5-FU over eight hours with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    , and were then randomly assigned to continue weekly BSA-based fixed dosing or individualized dosing based upon a single measurement of the 5-FU plasma concentration at steady state, calculated to achieve an area under the concentration x time curve (AUC) of 20 to 25",
"    <span class=\"nowrap\">",
"     mg-hr/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/70\">",
"     70",
"    </a>",
"    ]. Patients receiving AUC-based 5-FU dosing had significantly higher response rates, longer median survival, and less toxicity, including diarrhea.",
"   </p>",
"   <p>",
"    While these data are intriguing, the",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    regimen used in this trial is not typical for any disease.",
"   </p>",
"   <p>",
"    There are no published data on the benefits of pharmacokinetically-based dosing in patients receiving modern 5-FU-containing combination regimens, such as those containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , although one early report suggests promise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/71\">",
"     71",
"    </a>",
"    ]. Validation of the benefits of therapeutic drug monitoring in randomized trials for commonly used 5-FU-containing regimens is needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until such data are available, it is premature to conclude that pharmacokinetically-guided dosing should be integrated into clinical practice. Therapeutic drug monitoring is labor intensive, and most clinical practices do not have the technical infrastructure to adequately and rapidly process blood samples for clinical pharmacokinetic analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    is a rationally designed oral fluoropyrimidine that is converted to 5-FU in three sequential enzymatic reactions. The dose-limiting toxicities are diarrhea, palmar-plantar erythrodysesthesia, and neutropenia. Like 5-FU, capecitabine is contraindicated in patients with known DPD deficiency. (See",
"    <a class=\"local\" href=\"#H717960356\">",
"     'DPD deficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H204890821\">",
"    <span class=\"h4\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appear to be large regional differences in the tolerance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    and other fluoropyrimidines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/52\">",
"     52",
"    </a>",
"    ]. These differences might in part be based on population-specific pharmacogenomic variability (eg, Asian patients seem to tolerate fluoropyrimidines better than non-Asians, and although not studied according to ethnicity, genetic factors, such as single nucleotide polymorphisms, have been identified that are associated with capecitabine sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/72\">",
"     72",
"    </a>",
"    ]). However, differences in lifestyle and diet (eg, dietary folate intake) could also contribute.",
"   </p>",
"   <p>",
"    Because of these issues, the optimal dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , particularly for American patients remains undefined. The initially approved dose for treatment of metastatic breast and colorectal cancer was 2500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day for 14 of every 21 days, but later studies suggest that this dose is too high, particularly in American patients. Lower doses (beginning at 2000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day for 14 of every 21 days) may improve the therapeutic index without compromising efficacy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29528?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H12#H12\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Capecitabine as substitute for infusional 5-FU'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ftorafur",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two oral formulations of ftorafur, a 5-FU prodrug, have been developed that are in use in Japan; neither drug is available in the US.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      UFT is a combination of ftorafur (Tegafur) with uracil, which has been in widespread use in Japan for over 20 years. UFT is currently not available in the United States. Uracil competitively inhibits the enzyme DPD, leading to higher intratumoral concentrations of 5-FU.",
"      <br/>",
"      <br/>",
"      Grade 3 or 4 diarrhea is seen in up to 12 percent of patients treated with single-agent UFT and in 8 to 20 percent of those in whom UFT was given with LV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]. Prompt discontinuation of UFT at the onset of diarrhea usually prevents severe GI toxicity.",
"     </li>",
"     <li>",
"      S-1 is an oral formulation of ftorafur that contains an inhibitor of DPD plus potassium oxonate, a specific inhibitor of the enzyme orotate phosphoribosyl transferase, which is one of the enzymes responsible for phosphorylating 5-FU in the intestine. Phoshorylated 5-FU is thought to be mainly responsible for treatment-related diarrhea.",
"      <br/>",
"      <br/>",
"      In animal models, potassium oxonate is protective against 5-FU-induced diarrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]; in phase I and II clinical trials in Japan, the incidence of severe (grade 3 or 4) diarrhea with the S-1 formulation has been less than 10 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/77-79\">",
"       77-79",
"      </a>",
"      ]. In a randomized phase III Japanese trial of surgery followed by one year of S-1 chemotherapy versus surgery alone in gastric cancer, the incidence of grade 3 or 4 diarrhea was only 3.1 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/80\">",
"       80",
"      </a>",
"      ]. S-1 is also being evaluated in patients with advanced gastric cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44202?source=see_link&amp;anchor=H14#H14\">",
"       \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\", section on 'Cisplatin plus newer fluoropyrimidines'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of diarrhea associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    . Early-onset irinotecan-related diarrhea is often accompanied by other symptoms of cholinergic excess, including abdominal cramping, rhinitis, lacrimation, and salivation. The mean duration of symptoms is 30 minutes; it is usually well controlled by subcutaneous or IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Late diarrhea from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    is unpredictable, noncumulative, and occurs at all dose levels. In early clinical trials of irinotecan, late diarrhea and neutropenia were the main dose-limiting toxicities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Diarrhea of any grade was seen in 50 to 88 percent of patients and it was severe in 9 to 31 percent. Diarrhea has been less common in later studies because of the stricter adherence to management guidelines (including routine early institution of high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The median time to onset is about six days with the 350",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks schedule and 11 days with the weekly schedule (125",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/6,83\">",
"     6,83",
"    </a>",
"    ]. Late diarrhea is less common with the every three week schedule. In a randomized trial comparing the two administration schedules of single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , the incidence of severe diarrhea was significantly less with the every three week schedule (36 versus 19 percent for weekly therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/84\">",
"     84",
"    </a>",
"    ]. However, the incidence of cholinergic symptoms was significantly lower with weekly therapy (31 versus 61 percent). In some studies older age, low performance status and prior pelvic radiation were found to be predisposing factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/6\">",
"     6",
"    </a>",
"    ]. For unclear reasons, diarrhea is more common in whites than in blacks receiving irinotecan-based therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     UGT1A1 polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The active form of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    (SN-38) is further metabolized by the polymorphic enzyme uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1). In approximately 50 percent of the North American population, intratumoral enzymatic activity is reduced among those who inherit genetic polymorphisms such as the UGT1A1*28",
"    <span class=\"nowrap\">",
"     (7/7",
"    </span>",
"    variant) allele. Approximately 10 percent of North American patients are homozygous for the UGT1A1*28 allele (which is the cause of Gilbert's syndrome), and approximately 40 percent are heterozygous. In some studies, homozygotes (and to a lesser degree, heterozygotes) have had significantly higher rates of both diarrhea and myelosuppression with irinotecan. However, later analyses suggested that patients who inherit an UGT1A1*28 allele are mainly at risk for excess neutropenia and not diarrhea. This subject, as well as issues surrounding testing for the UGT1A1*28 allele, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H18#H18\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Irinotecan'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Irinotecan plus 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard regimen for treatment of metastatic CRC is the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , 5-FU and LV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Both irinotecan and 5-FU have overlapping toxicity profiles; a major concern with early studies of this triplet regimen was the potential for enhanced GI toxicity. The spectrum of GI toxicity with combined irinotecan plus 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    is schedule-dependent:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H717960378\">",
"    <span class=\"h5\">",
"     IFL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two United States Cooperative Group trials of bolus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus weekly 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (the IFL regimen), unacceptably high rates of early treatment-related mortality were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. In both trials, patients receiving irinotecan plus bolus 5-FU and leucovorin (either daily or weekly) had a threefold higher rate of treatment-related death than those enrolled on other arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/88\">",
"     88",
"    </a>",
"    ]. Most of the early deaths appeared due to a cluster of mainly GI symptoms, which included diarrhea, nausea, vomiting, abdominal cramping, that was typically accompanied by dehydration, neutropenia, fever and electrolyte abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Later reports have suggested that 60-day mortality rates among patients initiating chemotherapy for metastatic CRC with the IFL regimen (1.3 to 4.4 percent) are no higher than those reported for bolus 5-FU and LV (both by the Mayo regimen [6.7 percent] and the Roswell Park regimen [7.6 percent]), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    monotherapy (5.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. These later analyses likely reflect the increased understanding among oncologists of the risks associated with weekly bolus schedules of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    and the need for more aggressive early treatment of GI toxicity when it occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific therapeutic recommendations for the management of diarrhea (or abdominal cramping) in patients receiving IFL have been developed (",
"    <a class=\"graphic graphic_table graphicRef62912 \" href=\"mobipreview.htm?20/29/20955\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H717960451\">",
"    <span class=\"h5\">",
"     FOLFIRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;GI toxicity is less severe with other",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -containing regimens that utilize short-term infusional",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    (the de Gramont",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    regimen). In at least four trials, rates of grade 3 or 4 diarrhea with FOLFIRI (every other week irinotecan plus short-term infusional 5-FU and leucovorin) were between 10 and 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/87,93-95\">",
"     87,93-95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The better tolerability of regimens in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    is combined with infusional rather than bolus 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/93\">",
"     93",
"    </a>",
"    ] has led to the widespread use of FOLFIRI rather than IFL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H18#H18\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Irinotecan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Dose modifications for diarrhea",
"    </span>",
"   </p>",
"   <p>",
"    The US FDA-approved manufacturer's package insert provides guidelines for dose modification based on severity of diarrhea in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Oxaliplatin combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus 5-FU and LV have become the most widely chosen first-line chemotherapy regimen for metastatic colorectal cancer, at least in North America. In addition, oxaliplatin-containing regimens have also been shown to provide a survival benefit over nonoxaliplatin-containing regimens for adjuvant therapy of stage III colon cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H29#H29\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'First-line oxaliplatin plus 5-FU/LV'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H14#H14\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enterotoxicity with combined",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and 5-FU-containing chemotherapy is dependent on the schedule of 5-FU administration. With oxaliplatin combined with short-term infusional 5-FU (a regimen referred to as FOLFOX), rates of grade 3 or 4 diarrhea are less than 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/96-99\">",
"     96-99",
"    </a>",
"    ]. On the other hand, enterotoxicity is much more frequent and severe with regimens that combine oxaliplatin with weekly bolus 5-FU and LV (eg, FLOX) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/20\">",
"     20",
"    </a>",
"    ], and especially those that include daily bolus 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H29#H29\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'First-line oxaliplatin plus 5-FU/LV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was shown in the NSABP C-07 trial, a comparison of weekly bolus 5-FU and high dose LV (the Roswell park regimen) without or with (FLOX)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    as adjuvant therapy for stage II or III colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/20\">",
"     20",
"    </a>",
"    ]. During therapy, 79 of 1857 patients (4.3 percent) developed a syndrome of bowel wall injury characterized by hospitalization for management of severe diarrhea or dehydration, and radiographic or endoscopic evidence of bowel wall thickening or ulceration, and the incidence was significantly higher in patients assigned to FLOX as compared to",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (5.5 versus 3 percent). The incidence of bowel wall injury during chemotherapy was particularly high with FLOX as compared to 5-FU and LV in patients aged 60 or older (6.7 versus 2.9 percent) and in females (9.1 versus 3.9 percent).",
"   </p>",
"   <p>",
"    Enteric sepsis, characterized by grade 3 or worse diarrhea and grade 4 neutropenia (with or without bacteremia) occurred in 22 patients on FLOX and eight patients on",
"    <span class=\"nowrap\">",
"     5-FU/LV.",
"    </span>",
"    There were five deaths due to enteropathy, all in patients with enteric sepsis with or without bowel wall injury. These results underscore the need to closely monitor patients treated with adjuvant",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    chemotherapy for diarrhea and provide aggressive management of this symptom complex, particularly if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    has been added.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Capecitabine plus oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (XELOX) has also been intensely investigated given its convenience. A phase III comparison of XELOX (capecitabine at 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice a day for 14 days plus oxaliplatin 130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 every three weeks) with FOLFOX (continuous infusion of 5-FU at 2250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 48 hours on days 1, 8, 15, 22, 29, and 36, plus oxaliplatin 85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 15, and 29 every six weeks) in patients with metastatic colorectal cancer reported a significantly lower rate of grade 3 or 4 diarrhea with XELOX (14 versus 24 percent) but a significantly higher rate of grade 1 or 2 hyperbilirubinemia (37 versus 21 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/100\">",
"     100",
"    </a>",
"    ]. Similar rates of grade 3 or 4 diarrhea are reported in other trials as well. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H33#H33\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Capecitabine plus oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with inoperable or metastatic cancers of the esophagus, gastroesophageal junction or stomach, a phase III comparison of regimens containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and either 5-FU or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    reported a rate of grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    diarrhea of 12 percent for the combination of day 1 epirubicin 50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    day 1 oxaliplatin 130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and bid capecitabine 625",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (EOX) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44202?source=see_link\">",
"     \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pemetrexed",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     Pemetrexed",
"    </a>",
"    is an antifolate with activity in non-small cell lung cancer and mesothelioma. In phase II and III trials of pemetrexed monotherapy, diarrhea (typically grade 1 or 2) has been reported in about 10 to 15 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link\">",
"     \"Systemic treatment for unresectable malignant pleural mesothelioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3597507\">",
"    <span class=\"h3\">",
"     Cabazitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/47/31478?source=see_link\">",
"     Cabazitaxel",
"    </a>",
"    is a semisynthetic taxane that is approved for the treatment of advanced prostate cancer. Diarrhea is a frequent problem, developing in about one-half of treated patients, but it is severe (grade 3 or 4) in only 1 to 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/105-107\">",
"     105-107",
"    </a>",
"    ]. Nevertheless, in a pivotal phase III trial conducted in men with advanced prostate cancer, some deaths occurred in men treated with cabazitaxel that were attributed to diarrhea and electrolyte imbalance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/107\">",
"     107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=see_link&amp;anchor=H12#H12\">",
"     \"Chemotherapy in castrate-resistant prostate cancer\", section on 'Second-line chemotherapy: cabazitaxel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H204887561\">",
"    <span class=\"h3\">",
"     Bortezomib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea is commonly seen with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , a proteasome inhibitor used in the treatment of multiple myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/108\">",
"     108",
"    </a>",
"    ]. In the pivotal studies with this agent, diarrhea occurred in 51 percent of patients, with 8 percent of the events being grade 3 or 4.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H204887568\">",
"    <span class=\"h3\">",
"     Vorinostat",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/29/27093?source=see_link\">",
"     Vorinostat",
"    </a>",
"    , a novel histone deacetylase inhibitor, was approved by the FDA in 2006 for the management of cutaneous T cell-lymphoma. In the pivotal studies of this agent, diarrhea was observed in 52 percent of the patients with the great majority of these episodes being grade 1 or 2 events controllable by oral agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Molecularly targeted agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea is a common side effect of several molecularly targeted agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h4\">",
"     Small molecule EGFR inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea is common in patients receiving small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/110\">",
"     110",
"    </a>",
"    ]. It has been reported in up to 60 percent of patients, but it is only occasionally severe and typically can be easily managed by the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    . In some cases, diarrhea necessitates dose reduction or treatment interruptions.",
"   </p>",
"   <p>",
"    Synergistic toxicity may be a problem when these agents are combined with chemotherapy. Diarrhea has been a significant dose-limiting toxicity in a number of studies combining EGFR inhibitors with concurrent radiation and chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/111,112\">",
"     111,112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h4\">",
"     Small molecule inhibitors of VEGFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    are orally active inhibitors of multiple tyrosine kinases including the vascular endothelial growth factor receptor (VEGFR). Diarrhea is a prominent side effect of all VEGFR inhibitors. In clinical trials, diarrhea of any grade has been reported in 30 to 79 percent of patients (highest rates with vandetanib), with severe diarrhea (grade 3 or 4) in 3 to 17 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651229279#H1651229279\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Gastrointestinal toxicities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h4\">",
"     Bcr-Abl tyrosine kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    , an inhibitor of Bcr-Abl and other tyrosine kinases such as KIT, causes diarrhea in about 30 percent of the patients, but severe diarrhea is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/113\">",
"     113",
"    </a>",
"    ]. Similarly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , which targets BCR-ABL, KIT, and the SRC family of tyrosine kinase (among others), causes diarrhea in about 30 percent, which is severe in &lt;5 percent. On the other hand,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    , an inhibitor of Bcr-Abl and the Src family of kinases, causes diarrhea in a higher proportion of patients (76 to 84 percent) and is severe in about 9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=see_link&amp;anchor=H1349640#H1349640\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Bosutinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h4\">",
"     Lapatinib and pertuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     Lapatinib",
"    </a>",
"    , an orally active tyrosine kinase inhibitor that affects both the",
"    <span class=\"nowrap\">",
"     HER2/neu",
"    </span>",
"    (erbB-2) and the epidermal growth factor receptors (EGFR, also called erbB-1), causes diarrhea in approximately 40 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/115\">",
"     115",
"    </a>",
"    ]. Patients are typically managed with antidiarrheal agents; severe diarrhea may require hydration, electrolyte repletion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interruption of therapy (recommended for grade 3 toxicity (",
"    <a class=\"graphic graphic_table graphicRef65649 \" href=\"mobipreview.htm?22/60/23499\">",
"     table 1",
"    </a>",
"    ), and grade 1 or 2 toxicity that is complicated by moderate to severe abdominal cramping, grade 2 or worse nausea or vomiting (",
"    <a class=\"graphic graphic_table graphicRef69015 \" href=\"mobipreview.htm?31/24/32139\">",
"     table 4",
"    </a>",
"    ), decreased performance status, sepsis, fever, neutropenia, bleeding, or dehydration). Treatment can be reintroduced at a lower dose when diarrhea resolves to grade 1 or less.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/61/25557?source=see_link\">",
"     Pertuzumab",
"    </a>",
"    is a recombinant monoclonal antibody directed against HER2, but it does not require HER2 overexpression for activity. Treatment-related diarrhea is frequent, but not commonly severe. In a study of pertuzumab monotherapy in patients with metastatic breast cancer, diarrhea of any grade developed in 48 percent, but it was severe (grade 3 or 4) in only 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h4\">",
"     Temsirolimus and everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"     Temsirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , which are inhibitors of the mammalian target of rapamycin (mTOR), can cause diarrhea, but severe gastrointestinal toxicity is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/117,118\">",
"     117,118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h4\">",
"     Anti-EGFR monoclonal antibodies",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    is a chimeric IgG1 monoclonal antibody (MoAb) that binds to the extracellular domain of the EGFR, competitively inhibiting ligand binding. In contrast to small molecule EGFR inhibitors, cetuximab-related diarrhea is generally not severe:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II study of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      as monotherapy for 346 patients with metastatic colorectal cancer reported diarrhea of any grade in 12.7 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/119\">",
"       119",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When toxicities were reported regardless of attribution to treatment in a phase II study of patients with lung cancer treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      alone, 22.7 percent had diarrhea of any grade [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/120\">",
"       120",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rates of grade 3 or 4 diarrhea in studies of single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      are only 1.5 to 2 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/119-122\">",
"       119-122",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     Panitumumab",
"    </a>",
"    is a fully human IgG2 MoAb directed against the EGFR. A phase III comparison of best supportive care (BSC) with or without panitumumab reported diarrhea of any grade in 21 percent of patients receiving panitumumab (grade 3, 1 percent) compared to 11 percent with BSC alone (none grade 3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/123\">",
"     123",
"    </a>",
"    ]. Similar results are reported by others with panitumumab monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;General guidelines for the evaluation and management of CID are available (",
"    <a class=\"graphic graphic_table graphicRef52476 \" href=\"mobipreview.htm?7/16/7435\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef64251 \" href=\"mobipreview.htm?24/30/25062\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/125\">",
"     125",
"    </a>",
"    ]. Evaluation of the patient with CID begins with a history to determine the severity according to the NCI CTC grades (",
"    <a class=\"graphic graphic_table graphicRef65649 \" href=\"mobipreview.htm?22/60/23499\">",
"     table 1",
"    </a>",
"    ). The volume and duration of diarrhea should also be determined, and the history should include questions concerning foods or drugs that might play a contributory role (",
"    <a class=\"graphic graphic_table graphicRef57475 \" href=\"mobipreview.htm?11/40/11915\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the mucosal injury may lead to a temporary",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/62/14306?source=see_link\">",
"     lactase",
"    </a>",
"    deficiency, the ingestion of milk-containing foods may be important and should be specifically queried. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=see_link\">",
"     \"Lactose intolerance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It should also be appreciated that other factors can contribute to diarrhea in cancer patients treated with 5-FU or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    . These include intestinal infection (eg, C. difficile), radiation, and a history of prior intestinal resection. The presence of fever, dizziness, or abdominal pain should raise the possibility of a complication such as sepsis or bowel obstruction.",
"   </p>",
"   <p>",
"    A careful physical examination should be performed to assess for signs of volume depletion (eg, reduced skin turgor, hypotension, which may be primarily orthostatic, and low jugular venous pressure). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24457?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory testing should address both the complications and causes of CID. These include a standard chemistry screen, complete blood count, and stool",
"    <span class=\"nowrap\">",
"     culture/diagnostic",
"    </span>",
"    testing for toxin-producing strains of C. difficile. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of CID includes nonpharmacologic and pharmacologic interventions to slow the diarrhea and careful serial evaluation to rule out significant volume depletion or comorbidities that would require targeted intervention or hospitalization (",
"    <a class=\"graphic graphic_algorithm graphicRef64251 \" href=\"mobipreview.htm?24/30/25062\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/3\">",
"     3",
"    </a>",
"    ]. Initial nonpharmacologic measures include avoidance of foods that would aggravate the diarrhea (",
"    <a class=\"graphic graphic_table graphicRef57475 \" href=\"mobipreview.htm?11/40/11915\">",
"     table 6",
"    </a>",
"    ) and aggressive oral rehydration with fluids that contain water, salt, and sugar (since glucose promotes intestinal sodium absorption) such as broth or Gatorade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/126\">",
"     126",
"    </a>",
"    ]. These principles are similar to those used for infectious diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32025?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the adult with acute diarrhea in developed countries\", section on 'Oral rehydration solutions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Loperamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of the drug therapy of CID is the opiates.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     Loperamide",
"    </a>",
"    (Imodium) and diphenoxylate (Lomotil) are the most commonly used, and both are FDA-approved for this indication. Both give a rapid onset of action. Loperamide appears to be more effective and has been recommended in treatment guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/3\">",
"     3",
"    </a>",
"    ]. The standard dose of loperamide is an initial 4 mg dose followed by 2 mg every four hours or after every loose stool. This regimen is only moderately effective in CID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/125\">",
"     125",
"    </a>",
"    ], and a more aggressive regimen (4 mg initially, then 2 mg every two hours or 4 mg every four hours until diarrhea-free for 12 hours) is often required, particularly for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -induced diarrhea (",
"    <a class=\"graphic graphic_table graphicRef62912 \" href=\"mobipreview.htm?20/29/20955\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/3,83,127,128\">",
"     3,83,127,128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of the latter approach was illustrated in a study in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    (2 mg every two hours) was given for any episode of diarrhea beginning eight hours or more after the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/83\">",
"     83",
"    </a>",
"    ]. Patients stopped taking loperamide only after a 12-hour diarrhea-free period; if the diarrhea was not controlled after three consecutive days of continuous loperamide or the patient became volume depleted, loperamide was stopped and the patient was hospitalized for intravenous fluids. The loperamide protocol was followed in 46 of the 49 episodes of diarrhea in 23 patients; the median number of capsules taken was 21 (range, 5 to 72). Only one patient was hospitalized for failure to respond to loperamide, and no major toxicity was noted.",
"   </p>",
"   <p>",
"    In another report,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    was given weekly at 125",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for four weeks with two weeks rest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/127\">",
"     127",
"    </a>",
"    ]. The prevalence of grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    diarrhea fell from 56 to 9 percent with strict adherence to the high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    regimen.",
"   </p>",
"   <p>",
"    The use of opium derivatives (eg, deodorized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/3/35893?source=see_link\">",
"     tincture of opium",
"    </a>",
"    , DTO) is discussed separately (see",
"    <a class=\"local\" href=\"#H31\">",
"     'Other antidiarrheal agents'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Octreotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    , a synthetic long-acting somatostatin analog, acts via several mechanisms: decreased secretion of a number of hormones, such as vasoactive intestinal peptide (VIP); prolongation of intestinal transit time; and reduced secretion and increased absorption of fluid and electrolytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/129\">",
"     129",
"    </a>",
"    ]. It is approved by the Food and Drug Administration for the treatment of diarrhea related to VIP-secreting tumors and symptoms due to carcinoid syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16311?source=see_link\">",
"     \"The VIPoma syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    is also beneficial in patients with CID from fluoropyrimidines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , and 5-FU-based chemoradiotherapy although the optimal dose has not been determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/125,130-133\">",
"     125,130-133",
"    </a>",
"    ]. Although one randomized trial in 41 5-FU-treated patients showed that octreotide was more effective than standard-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    (90 versus 15 percent resolution of diarrhea by day 3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/125\">",
"     125",
"    </a>",
"    ], octreotide is generally reserved as a second-line therapy for patients who do not respond to high dose loperamide because of its high cost and the general effectiveness of loperamide, (see",
"    <a class=\"local\" href=\"#H32\">",
"     'Summary and consensus recommendations'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The recommended starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    is 100 to 150 microg subcutaneously, three times a day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/3,134\">",
"     3,134",
"    </a>",
"    ]. However, several reports suggest that higher doses (500 microg) may be more effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/130,135,136\">",
"     130,135,136",
"    </a>",
"    ]. The available data support upward titration of the dose (up to 2500 microg three times daily) in nonresponders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/3,130,134\">",
"     3,130,134",
"    </a>",
"    ]. The side effects of octreotide are generally mild, including bloating, cramping, flatulence and fat malabsorption. Hypersensitivity-like reactions and hypoglycemia can occur at higher doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Other antidiarrheal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other antidiarrheal agents have been evaluated in patients with CID.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticholinergic drugs are not commonly used because of side effects. However, they can be helpful when diarrhea is associated with significant cramping.",
"     </li>",
"     <li>",
"      Absorbents (eg, pectin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"       aluminum hydroxide",
"      </a>",
"      ) and adsorbents (eg, kaolin, charcoal) bind osmotically active substances and can be effective adjunctive therapy in patients with mild diarrhea.",
"     </li>",
"     <li>",
"      Deodorized",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/3/35893?source=see_link\">",
"       tincture of opium",
"      </a>",
"      (DTO) is a widely used antidiarrheal agent, despite the absence of literature reports supporting efficacy for treatment of chemotherapy-induced diarrhea. DTO contains the equivalent of 10",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      . The recommended dose is 10 to 15 drops in water every three to four hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/125\">",
"       125",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An alternative is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/32/20997?source=see_link\">",
"       paregoric",
"      </a>",
"      , camphorated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/3/35893?source=see_link\">",
"       tincture of opium",
"      </a>",
"      , a less concentrated preparation that contains the equivalent of 0.4",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      . The recommended dose is 5mL (one teaspoonful) in water every three to four hours.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35285?source=see_link\">",
"       Bismuth",
"      </a>",
"      subsalicylate has both antiinflammatory and antibacterial actions but has not been evaluated for the treatment of CID.",
"     </li>",
"     <li>",
"      Acetorphan is an enkephalinase inhibitor that blocks epithelial cyclic AMP-mediated secretion. It has moderate activity in patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -induced diarrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       Budesonide",
"      </a>",
"      is a glucocorticoid that has high affinity for the glucocorticoid receptor but low systemic activity due to extensive first-pass metabolism in the liver. Budesonide is effective for inducing remission in ileal or ileal cecal Crohn's disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17962?source=see_link\">",
"       \"Investigational therapies in the medical management of Crohn's disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At least one report suggests possible efficacy for oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    in patients with diarrhea caused by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/137\">",
"     137",
"    </a>",
"    ]. In a phase I study involving 14 patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    -refractory grade 3 or 4 diarrhea, severity was reduced by at least two grades in 86 percent of the irinotecan-treated patients and 57 percent of those receiving 5-FU.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Summary and consensus recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations of a consensus conference on the management of CID were published in 1998 and updated in 2004. Guidelines for evaluation and management of patients with CID are presented in the following figures (",
"    <a class=\"graphic graphic_table graphicRef52476 \" href=\"mobipreview.htm?7/16/7435\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef64251 \" href=\"mobipreview.htm?24/30/25062\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/3\">",
"     3",
"    </a>",
"    ]. The tempo and specific nature of treatment is guided by the classification of the symptom constellation as complicated or uncomplicated. Uncomplicated patients may be managed conservatively in the outpatient setting (at least initially), while those with severe diarrhea or a potentially exacerbating condition (eg, abdominal cramping, nausea, vomiting, fever, sepsis, neutropenia or bleeding) should be admitted to the hospital and treated aggressively with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , intravenous fluids, antibiotics, and a diagnostic workup.",
"   </p>",
"   <p>",
"    Specific recommendations from an expert panel for patients receiving the IFL regimen (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef62912 \" href=\"mobipreview.htm?20/29/20955\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/89\">",
"     89",
"    </a>",
"    ]. However, the use of IFL has been abandoned for treatment of metastatic colorectal cancer by most oncologists in favor of the better tolerated and similarly effective FOLFIRI regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H20#H20\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Irinotecan plus 5-FU'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Special caution is advised for elderly patients, particularly women, who seem more susceptible for other chemotherapy-related complications, such as neutropenia and stomatitis that can exacerbate their condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38250?source=see_link\">",
"     \"Oral toxicity associated with chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Investigational approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several attempts have been made to increase the glucuronidation or reduce the deconjugation of SN-38 by intestinal bacteria. These include increasing glucuronidation by coadministration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/138\">",
"     138",
"    </a>",
"    ], and reducing deconjugation via the administration of oral, nonabsorbable antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/10\">",
"     10",
"    </a>",
"    ], or of kampo, a Japanese herbal medicine that contains natural glucuronides that inhibit bacterial glucuronidases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/139\">",
"     139",
"    </a>",
"    ]. Other approaches involve inhibition of biliary excretion of SN-38 by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , or inhibitors of P-glycoprotein or the canalicular multispecific organic anion transporter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/140,141\">",
"     140,141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In preliminary reports,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    and oral",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"      neomycin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"      bacitracin",
"     </a>",
"    </span>",
"    have all been reported to lessen the incidence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -related late diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/142-144\">",
"     142-144",
"    </a>",
"    ], although at least one small randomized trial has not confirmed a major role for neomycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Keratinocyte growth factor stimulates the proliferation and differentiation of epithelial cells. In animal models, pretreatment with keratinocyte growth factor significantly reduced the gastrointestinal (GI) toxicity associated with chemotherapeutic agents or radiation due in part to increased crypt survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/146\">",
"     146",
"    </a>",
"    ]. In another animal study, the administration of interleukin (IL)-15 dramatically diminished",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"     -induced",
"    </span>",
"    GI toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of these agents remain investigational for treatment of chemotherapy-related diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Is there a role for prophylaxis?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is a well-recognized risk of diarrhea with certain chemotherapy regimens (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , 5-FU with high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    administered as a five day bolus once monthly), few studies have investigated the potential benefit of prophylactic antidiarrheal therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"       Activated charcoal",
"      </a>",
"      &mdash; Activated charcoal may have a role in preventing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -induced diarrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/148\">",
"       148",
"      </a>",
"      ]. In one study, 28 patients received activated charcoal during the first treatment cycle, but not the second. The incidence of grade 3 or 4 diarrhea increased from 7 to 25 percent between cycles 1 and 2, and more patients required 10 or more tablets of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"       loperamide",
"      </a>",
"      without prophylaxis.",
"     </li>",
"     <li>",
"      Oral alkalinization &mdash; A complicated regimen of oral alkalinization of the intestinal lumen in conjunction with control of defecation may have been beneficial in a Japanese case-control study of patients undergoing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/149\">",
"       149",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Probiotics &mdash; An interesting but investigational strategy is oral administration of \"probiotics\", microorganisms such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32004?source=see_link\">",
"       Lactobacillus",
"      </a>",
"      species. Based on the success of this approach in children afflicted by diarrheal illnesses as well as for antibiotic-induced diarrhea, a trial was conducted in 150 patients receiving two different 5-FU-based chemotherapy regimens in which the random assignment was to receive or not receive Lactobacillus rhamnosus GG",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fiber supplementation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/150\">",
"       150",
"      </a>",
"      ]. Patients who received Lactobacillus supplements had significantly less grade 3 and 4 diarrhea (22 versus 37 percent), and required fewer hospitalizations and dose reductions due to bowel toxicity. However, this group also had a trend toward a higher number of neutropenic complications. Fiber intake did not alter chemotherapy toxicity. Interpretation of this trial is limited by the lack of stratification for method of chemotherapy administration. Further studies are be needed to assess the overall benefit of such interventions.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"       Octreotide",
"      </a>",
"      &mdash; In contrast to its therapeutic benefit, the role of prophylactic octreotide is unproven [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/151-153\">",
"       151-153",
"      </a>",
"      ]. In a preliminary report of the only randomized study to compare octreotide long-acting release (LAR) versus a no-treatment control arm in 139 patients receiving chemotherapy for colorectal cancer with FU,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      , octreotide LAR did not prevent or reduce the severity of chemotherapy-induced diarrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/153\">",
"       153",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antidiarrheal treatment is not a standard approach for any regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     CONSTIPATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation can be defined as a decreased frequency of defecation (usually less than three bowel movements per week) accompanied by discomfort or difficulty. It is a common problem in patients with cancer, usually being due to a combination of poor oral intake and drugs, such as opioid analgesics or antiemetic agents, that slow intestinal transit time. As an example, 5HT3 receptors are present on enteric neurons, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    was shown to slow colonic transit time in healthy subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2516?source=see_link\">",
"     Methylnaltrexone",
"    </a>",
"    , a pure opiate antagonist that does not cross the blood brain barrier, may be useful to treat constipation when opioid analgesics are a significant causal factor for the constipation. Methylnaltrexone does not block the analgesic activity of opiates or precipitate opiate withdrawal. In a randomized study, subcutaneous methylnaltrexone administration showed excellent efficacy and did not affect central analgesia or precipitate opioid withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/155\">",
"     155",
"    </a>",
"    ]. As a result, methylnaltrexone received FDA approval in 2008 for the management of opioid-induced constipation in patients with advanced illness who are receiving palliative care. Its use in other settings, such as medication-induced constipation, has not been carefully investigated yet. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link&amp;anchor=H2#H2\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Bowel issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Vinca alkaloids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation is rarely a dose-limiting toxicity for chemotherapeutic agents except for the vinca alkaloids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    ), especially vincristine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\"",
"    </a>",
"    .) These drugs have pronounced neuropathic effects and reduce GI transit time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/156\">",
"     156",
"    </a>",
"    ]. The constipating effect of vinca alkaloid therapy is usually apparent after the first dose and is typically not cumulative. It is most prominent three to ten days after chemotherapy and then resolves in most cases after a few days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/157\">",
"     157",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Constipation occurs in one-quarter to one-third of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/158,159\">",
"     158,159",
"    </a>",
"    ] and is severe in 2 to 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/158,160\">",
"     158,160",
"    </a>",
"    ]. In one series of 392 patients, 2.8 percent required hospitalization for adynamic ileus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     Vincristine",
"    </a>",
"    -induced constipation is more severe at higher doses (above 2 mg). This was illustrated in a report of 104 patients with Hodgkin's or non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/161\">",
"     161",
"    </a>",
"    ]. Vincristine was given in a noncapped dose of 1.4",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    and 90 percent of patients received more than 2 mg in the first dose. Severe constipation occurred in 10 percent. Rapid improvement usually occurred within a few weeks after the cessation of therapy.",
"   </p>",
"   <p>",
"    Constipation is also more frequent and may be more severe (presenting as a bowel obstruction or paralytic ileus) in patients treated with the liposome-encapsulated version of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    (Marqibo",
"    <sup>",
"     &reg;",
"    </sup>",
"    ), which is approved only for treatment of refractory adult acute lymphoblastic leukemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21753?source=see_link&amp;anchor=H2914156#H2914156\">",
"     \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\", section on 'Liposomal vincristine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Thalidomide and analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    and its analogs",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    have shown promise for the treatment of refractory multiple myeloma and other disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=see_link\">",
"     \"Treatment of relapsed or refractory multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common toxicity with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , beside sedation, is constipation. In a major myeloma trial, constipation developed in 35 percent of patients at 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and in 59 percent at 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/162\">",
"     162",
"    </a>",
"    ]. These rates seem higher than those observed in a phase II trial of thalidomide (starting dose 800 mg daily) in patients with recurrent high-grade glioma, in which constipation was the most common toxicity, but only occurred in 19 percent of patients; no severe episodes were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/163\">",
"     163",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    -induced constipation is dose-dependent, appears early after the initiation of therapy (within two to four days) in most patients and is more severe in the elderly and in those receiving opioid analgesics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/164\">",
"     164",
"    </a>",
"    ]. The mechanism might be neuromuscular inertia with resultant hypotonia. Thalidomide-induced hypothyroidism should be considered in patients with persistent constipation or if it appears late in the disease course.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     Lenalidomide",
"    </a>",
"    , an immunomodulatory agent derived from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , is also associated with constipation, although it is rarely severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/165-167\">",
"     165-167",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    has been associated with diarrhea or constipation in about one-third of treated patients, none of which were severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/168\">",
"     168",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19930479\">",
"    <span class=\"h2\">",
"     Vandetanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     Vandetanib",
"    </a>",
"    is a multitargeted inhibitor of several tyrosine kinases. In clinical trials involving patients with medullary thyroid cancer and lung cancer, vandetanib was associated with constipation in 9 to 37 percent of patients, with 0 to 3 percent severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/169-171\">",
"     169-171",
"    </a>",
"    ]. Vandetanib is more often associated with diarrhea. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Small molecule inhibitors of VEGFR'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of chemotherapy-induced constipation begins with anticipation and prevention. Laxatives should be started at the first sign of constipation or should be given routinely to prevent constipation. The most frequently used laxatives are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/41/22165?source=see_link\">",
"     docusate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40276?source=see_link\">",
"     senna",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    . If these agents are not effective, magnesium salts, Miralax,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    are often effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/172\">",
"     172",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=see_link\">",
"     \"Management of chronic constipation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     COLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three types of colitis have been described in association with chemotherapy: neutropenic enterocolitis, ischemic colitis, and C. difficile-associated colitis. In addition, an immune-mediated colitis has been reported in patients treated with anti-CTLA-4 antibody therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Neutropenic enterocolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenic enterocolitis (a form of necrotizing enterocolitis or typhlitis) is one of the most common GI complications in leukemic patients who are undergoing induction therapy, and can occur in other malignancies and following stem-cell supported high dose chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/173,174\">",
"     173,174",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis, risk factors, diagnosis, and management of patients with neutropenic enterocolitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27125?source=see_link\">",
"     \"Typhlitis (neutropenic enterocolitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Ischemic colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of cases of ischemic colitis have been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    -containing regimens in patients with metastatic breast cancer, including 3 of 14 patients in a phase I study of docetaxel and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/175,176\">",
"     175,176",
"    </a>",
"    ]. The typical onset is four to ten days following administration. The clinical manifestations are similar to neutropenic enterocolitis but not all patients are neutropenic at presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Clostridium difficile-associated colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clostridium difficile colitis is a common problem in patients with cancer, mostly due to the high rate of oral antibiotic use and hospitalization. However, several reports have described this complication in patients without any prior antibiotic use following chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/177-179\">",
"     177-179",
"    </a>",
"    ]. The proposed mechanism is chemotherapy-induced intestinal damage that facilitates the proliferation of C. difficile.",
"   </p>",
"   <p>",
"    Frequent occurrence of C. difficile-related diarrheal episodes has been reported in patients treated with paclitaxel-containing regimens, especially with the use of \"dose-dense\" regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/180\">",
"     180",
"    </a>",
"    ]. The spectrum of illness varies from mild to fulminant; management is the same as with nonchemotherapy-associated cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Ipilimumab and immune-breakthrough enterocolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"     Ipilimumab",
"    </a>",
"    is a monoclonal antibody directed against CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on the T cell surface. As a treatment for advanced melanoma, the presumed mechanism of action of ipilimumab is to break down tolerance to the tumor-associated antigens in the melanoma. At the same time, this may result in decreased tolerance to self antigens. A wide range of immune-mediated adverse events have been observed in patients treated with ipilimumab, including enterocolitis, which can be serious or life-threatening. The manifestations and management of ipilimumab-induced enterocolitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=see_link&amp;anchor=H177442771#H177442771\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7625?source=see_link\">",
"     \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     INTESTINAL PERFORATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel perforation is an uncommonly encountered complication that seems to be associated with antiangiogenic agents, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a monoclonal antibody targeting the vascular endothelial growth factor (VEGF).",
"   </p>",
"   <p>",
"    This complication is not unique to agents that target angiogenesis. Bowel perforation has also been seen (albeit rarely) with other tumors involving the GI tract that respond rapidly to conventional cytotoxic chemotherapy (eg, GI tract lymphomas). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3930?source=see_link\">",
"     \"Management of gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Molecularly-targeted angiogenesis inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;All VEGF targeted therapies, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    , and the orally active antiangiogenic tyrosine kinase inhibitors, can cause gastrointestinal perforation (GIP), although this complication is best described in patients receiving bevacizumab. GIP has been reported in patients treated with bevacizumab for a variety of malignancies, but are most often described in the setting of metastatic colorectal cancer (mCRC) and epithelial ovarian cancer (EOC). GIP can occur anywhere along the GI tract. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227451#H1651227451\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Intestinal perforation/fistula formation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although several risk factors have been described for GIP during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    treatment, bowel perforation may occur even in the absence of predisposing risk factors, and it remains difficult to predict which patients will develop this complication. Many cases involve perforation of an in situ bowel primary. However, GIP can also occur at previously resected primary sites, often in the setting of previous irradiation or a prior anastomotic leak. GIP can also occur during bevacizumab treatment of malignancies that lack disease within the peritoneal cavity (eg, primary malignant brain tumors).",
"   </p>",
"   <p>",
"    In order to minimize the risk of GIP and fistula formation, at least 28 days (preferably six to eight weeks) should elapse between surgery and last dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , except in emergency situations. Clinicians should maintain a high index of suspicion for GIP in patients who develop acute abdominal pain while receiving bevacizumab, even if they have no apparent risk factors.",
"   </p>",
"   <p>",
"    Perforation may be asymptomatic, or it can present with abdominal pain from peritoneal contamination, free air, hemoperitoneum, or an intraabdominal abscess. Patients with confirmed or highly suspected GIP whose overall condition is unstable secondary to the GIP should be considered for immediate surgical repair or diversion. Those who are more stable can be considered for less invasive management strategies such as bowel rest and broad-spectrum antibiotics with or without percutaneous drainage of concurrent abscesses. The timing of the presentation, the patient&rsquo;s overall condition, their goals and wishes, and overall prognosis are important factors in the decision to explore these patients surgically. This subject is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227451#H1651227451\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Intestinal perforation/fistula formation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Thalidomide in multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least one case report describes four cases of bowel perforation in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    for multiple myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/181\">",
"     181",
"    </a>",
"    ]. The true incidence is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Erlotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of GI perforation (some fatal) have also been reported in patients receiving the small molecule epidermal growth factor receptor (EGFR) inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/182\">",
"     182",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=see_link&amp;anchor=H177152529#H177152529\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\", section on 'EGFR TKI toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H204887526\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal (GI) toxicity due to chemotherapeutic drugs is a common problem in cancer patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chemotherapy-induced diarrhea (CID) is most commonly described with fluoropyrimidines (particularly 5-fluorouracil [5-FU] and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/47/31478?source=see_link\">",
"       cabazitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/29/27093?source=see_link\">",
"       vorinostat",
"      </a>",
"      , and several molecularly targeted agents (including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      , agents targeting the epidermal growth factor receptor [EGFR]). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diarrhea'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      CID can be debilitating and in some cases, life-threatening. Treatment includes nonpharmacologic and pharmacologic interventions to slow the diarrhea and careful serial evaluation to rule out significant volume depletion or comorbidities that would require targeted intervention or hospitalization. The recommendations of a consensus conference on evaluation and management of patients with CID are presented in the following (",
"      <a class=\"graphic graphic_table graphicRef52476 \" href=\"mobipreview.htm?7/16/7435\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef64251 \" href=\"mobipreview.htm?24/30/25062\">",
"       algorithm 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/23/42362/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Treatment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Prophylactic antidiarrheal treatment is not a standard approach for any regimen. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Is there a role for prophylaxis?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients treated with oral regimens associated with diarrhea should be instructed to report changes in bowel patterns immediately to ensure prompt treatment and interruption of therapy if needed.",
"     </li>",
"     <li>",
"      A test is commercially available that might identify patients who are at risk for severe toxicity from fluoropyrimidines (TheraGuide 5-FU) based upon genotype. Use of the TheraGuide 5-FU assay is indicated in any patient experiencing severe toxicity after receiving a fluoropyrimidine-containing regimen. (See",
"      <a class=\"local\" href=\"#H44530323\">",
"       'Pharmacogenetic testing for DPYD and TYMS variants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Constipation is rarely a dose-limiting toxicity for chemotherapeutic agents except for the vinca alkaloids, especially",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Vinca alkaloids'",
"      </a>",
"      above.) Treatment should focus on anticipation and prevention. Laxatives should be started at the first sign of constipation or should be given routinely to prevent constipation. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Constipation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three types of colitis have been described in association with chemotherapy: neutropenic enterocolitis, ischemic colitis, and C. difficile-associated colitis. In addition, an immune-mediated colitis has been reported in patients treated with anti-CTLA-4 antibody therapy. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Colitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bowel perforation is an uncommonly encountered complication that seems to be associated with antiangiogenic agents, particularly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , a monoclonal antibody targeting the vascular endothelial growth factor (VEGF). (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Intestinal perforation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      This complication is not unique to agents that target angiogenesis. Bowel perforation has also been seen (albeit rarely) with other tumors involving the GI tract that respond rapidly to conventional cytotoxic chemotherapy (eg, GI tract lymphomas). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3930?source=see_link\">",
"       \"Management of gastrointestinal lymphomas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/1\">",
"      Milles SS, Muggia AL, Spiro HM. Colonic histological changes induced by 5-fluorouracil. Gastroenterology 1962; 43:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/2\">",
"      Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1995; 87:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/3\">",
"      Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22:2918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/4\">",
"      Abigerges D, Chabot GG, Armand JP, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/5\">",
"      Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998; 16:2745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/6\">",
"      Hecht JR. Gastrointestinal toxicity or irinotecan. Oncology (Williston Park) 1998; 12:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/7\">",
"      Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51:4187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/8\">",
"      Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54:3723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/9\">",
"      Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 8:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/10\">",
"      Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56:3752.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute Common Toxicity Criteria file://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (Accessed on March 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/12\">",
"      Mertz HR, Beck CK, Dixon W, et al. Validation of a new measure of diarrhea. Dig Dis Sci 1995; 40:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/13\">",
"      Grem JL, Shoemaker DD, Petrelli NJ, Douglass HO Jr. Severe life-threatening toxicities observed in study using leucovorin with 5-fluorouracil. J Clin Oncol 1987; 5:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/14\">",
"      Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/15\">",
"      Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995; 13:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/16\">",
"      Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/17\">",
"      Petrelli N, Douglass HO Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/18\">",
"      Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/19\">",
"      Cascinu S, Barni S, Labianca R, et al. Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. Support Care Cancer 1997; 5:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/20\">",
"      Kuebler JP, Colangelo L, O'Connell MJ, et al. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer 2007; 110:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/21\">",
"      Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002; 20:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/22\">",
"      Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 2005; 103:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/23\">",
"      Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/24\">",
"      Maring JG, van Kuilenburg AB, Haasjes J, et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 2002; 86:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/25\">",
"      Ezzeldin H, Johnson MR, Okamoto Y, Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 2003; 9:3021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/26\">",
"      Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 1991; 68:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/27\">",
"      Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996; 2:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/28\">",
"      Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004; 4:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/29\">",
"      Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999; 5:2672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/30\">",
"      van Kuilenburg AB, Meinsma R, Zonnenberg BA, et al. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 2003; 9:4363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/31\">",
"      Yang CG, Ciccolini J, Blesius A, et al. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol 2011; 67:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/32\">",
"      Mattison LK, Fourie J, Desmond RA, et al. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006; 12:5491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/33\">",
"      Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006; 5:2895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/34\">",
"      van Kuilenburg AB, De Abreu RA, van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 2003; 40:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/35\">",
"      Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 2001; 41:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/36\">",
"      Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002; 8:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/37\">",
"      Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/38\">",
"      Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g&gt;a mutation. Int J Cancer 2002; 101:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/39\">",
"      Raida M, Schwabe W, H&auml;usler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 2001; 7:2832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/40\">",
"      Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS14 + 1G&gt;A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002; 12:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/41\">",
"      Deenen MJ, Tol J, Burylo AM, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17:3455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/42\">",
"      Loganayagam A, Arenas-Hernandez M, Fairbanks L, et al. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients. Cancer Chemother Pharmacol 2010; 65:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/43\">",
"      Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 2005; 11:8699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/44\">",
"      Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63:2898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/45\">",
"      Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/46\">",
"      Ichikawa W, Takahashi T, Suto K, et al. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res 2006; 12:3928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/47\">",
"      Lecomte T, Ferraz JM, Zinzindohou&eacute; F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004; 10:5880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/48\">",
"      Thomas HR, Ezzeldin HH, Guarcello V, et al. Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics 2008; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/49\">",
"      Thomas HR, Ezzeldin HH, Guarcello V, et al. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics 2007; 17:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/50\">",
"      Ezzeldin HH, Diasio RB. Predicting fluorouracil toxicity: can we finally do it? J Clin Oncol 2008; 26:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/51\">",
"      Braun MS, Richman SD, Thompson L, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 2009; 27:5519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/52\">",
"      Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/53\">",
"      Lewis CJ, Crane NT, Wilson DB, Yetley EA. Estimated folate intakes: data updated to reflect food fortification, increased bioavailability, and dietary supplement use. Am J Clin Nutr 1999; 70:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/54\">",
"      Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22:3766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/55\">",
"      Sharma R, Rivory L, Beale P, et al. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer 2006; 94:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/56\">",
"      Johnson MR, Yan J, Shao L, et al. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 1997; 696:183.",
"     </a>",
"    </li>",
"    <li>",
"     TheraGuide 5-FU, Myriad Genetics Laboratories file://www.myriadtests.com/hcp/theraguide_testing_process.htm (Accessed on March 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/58\">",
"      Mattison LK, Ezzeldin H, Carpenter M, et al. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 2004; 10:2652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/59\">",
"      Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 2007; 43:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/60\">",
"      van Kuilenburg AB. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question. Cancer Invest 2006; 24:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/61\">",
"      Wilson KS, Fitzgerald CA, Barnett JB, et al. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience. Cancer Invest 2007; 25:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/62\">",
"      Deenen MJ, Terpstra WE, Cats A, et al. Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine. Ann Intern Med 2010; 153:767.",
"     </a>",
"    </li>",
"    <li>",
"     Bamat MK, Tremmel R, O'Neil JD, et al. Uridine triacetate: An orally administered, life-saving antidote for 5-FU overdose (abstract #9084). J Clin Oncol 2010; 28:656s.",
"    </li>",
"    <li>",
"     von Borstel R, O'Neil JD, Saydoff JA, et al. Uridine triacetate for lethal 5-FU toxicity due to dihydropyrimidine dehydrogenase (DPD) deficiency (abstract ). J Clin Oncol 2010 (suppl abstract e13505).",
"    </li>",
"    <li>",
"     Information on availability of uridine triacetate available by telephone (443-831-5626, US) or online at file://www.wellstattherapeutics.com/therapeutics/html/randd/compounds/visto-5fu.html (Accessed on March 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/66\">",
"      Gamelin E, Boisdron-Celle M, Gu&eacute;rin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999; 17:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/67\">",
"      Saam J, Critchfield GC, Hamilton SA, et al. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. Clin Colorectal Cancer 2011; 10:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/68\">",
"      Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 2009; 101:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/69\">",
"      Kaldate RR, Haregewoin A, Grier CE, et al. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist 2012; 17:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/70\">",
"      Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/71\">",
"      Capitain O, Asevoaia A, Boisdron-Celle M, et al. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer 2012; 11:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/72\">",
"      O'Donnell PH, Stark AL, Gamazon ER, et al. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer 2012; 118:4063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/73\">",
"      Sulkes A, Benner SE, Canetta RM. Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. J Clin Oncol 1998; 16:3461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/74\">",
"      Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol 1998; 16:2877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/75\">",
"      Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53:4004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/76\">",
"      Takechi T, Nakano K, Uchida J, et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997; 39:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/77\">",
"      Rino Y, Takanashi Y, Yukawa N, et al. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer. Anticancer Res 2006; 26:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/78\">",
"      Kobayashi M, Tsuburaya A, Nagata N, et al. A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer. Gastric Cancer 2006; 9:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/79\">",
"      Goto A, Yamada Y, Yasui H, et al. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2006; 17:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/80\">",
"      Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/81\">",
"      Pazdur R. Irinotecan: toward clinical end points in drug development. Oncology (Williston Park) 1998; 12:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/82\">",
"      Rothenberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol 1996; 23:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/83\">",
"      Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/84\">",
"      Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/85\">",
"      Sanoff HK, Sargent DJ, Green EM, et al. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol 2009; 27:4109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/86\">",
"      Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/87\">",
"      Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/88\">",
"      Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/89\">",
"      Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19:3801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/90\">",
"      Delaunoit T, Goldberg RM, Sargent DJ, et al. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 2004; 101:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/91\">",
"      Miller L, Emanuel D, Elfring G, et al. 60-day, all-cause mortality with first-line irinotecan/fluorouracil/leucovorin (IFL) or fluorouracil/leucovorin for metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 2002; 20:129a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/92\">",
"      Elfring G, Emanuel D, Rostagi R, et al. Patterns of use and mortality in the community oncology practice setting among patients receiving first-line weekly bolus irinotecan/5-fluorouracil/leucovorin (IFL) for metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 2002; 20:133a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/93\">",
"      Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25:4779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/94\">",
"      Tournigand C, Andr&eacute; T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/95\">",
"      Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/96\">",
"      de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/97\">",
"      Scheithauer W, Kornek GV, Raderer M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 1999; 17:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/98\">",
"      Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/99\">",
"      Andr&eacute; T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/100\">",
"      D&iacute;az-Rubio E, Tabernero J, G&oacute;mez-Espa&ntilde;a A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25:4224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/101\">",
"      Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/102\">",
"      Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/103\">",
"      Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/104\">",
"      Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemona&iuml;ve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 2008; 3:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/105\">",
"      Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/106\">",
"      Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/107\">",
"      de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/108\">",
"      Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/109\">",
"      Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/110\">",
"      Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005; 23:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/111\">",
"      Messersmith WA, Laheru DA, Senzer NN, et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 2004; 10:6522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/112\">",
"      Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 2006; 24:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/113\">",
"      Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003; 21:1637.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf?et_cid=29953027&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203341lbl.pdf (Accessed on September 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/115\">",
"      Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007; 12:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/116\">",
"      Cort&eacute;s J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/117\">",
"      Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/118\">",
"      Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/119\">",
"      Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24:4914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/120\">",
"      Hanna N, Lilenbaum R, Ansari R, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006; 24:5253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/121\">",
"      Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/122\">",
"      Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/123\">",
"      Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/124\">",
"      Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007; 110:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/125\">",
"      Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993; 11:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/126\">",
"      DuPont HL. Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1997; 92:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/127\">",
"      Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/128\">",
"      Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/129\">",
"      Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/130\">",
"      Wadler S, Haynes H, Wiernik PH. Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 1995; 13:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/131\">",
"      Petrelli NJ, Rodriguez-Bigas M, Rustum Y, et al. Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. Cancer 1993; 72:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/132\">",
"      Gebbia V, Carreca I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993; 4:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/133\">",
"      Topkan E, Karaoglu A. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. Oncology 2006; 71:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/134\">",
"      Harris AG, O'Dorisio TM, Woltering EA, et al. Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Dig Dis Sci 1995; 40:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/135\">",
"      Barbounis V, Koumakis G, Vassilomanolakis M, et al. Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 2001; 9:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/136\">",
"      Goumas P, Naxakis S, Christopoulou A, et al. Octreotide Acetate in the Treatment of Fluorouracil-Induced Diarrhea. Oncologist 1998; 3:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/137\">",
"      Lenfers BH, Loeffler TM, Droege CM, Hausamen TU. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol 1999; 10:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/138\">",
"      Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 1997; 39:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/139\">",
"      Takasuna K, Kasai Y, Kitano Y, et al. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn J Cancer Res 1995; 86:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/140\">",
"      Gupta E, Safa AR, Wang X, Ratain MJ. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res 1996; 56:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/141\">",
"      Ratain MJ. Insights into the pharmacokinetics and pharmacodynamics of irinotecan. Clin Cancer Res 2000; 6:3393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/142\">",
"      Kehrer DF, Sparreboom A, Verweij J, et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001; 7:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/143\">",
"      Govindarajan R, Heaton KM, Broadwater R, et al. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 2000; 356:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/144\">",
"      Fiorentini G, Rossi S, Lanzanova G, et al. Potential use of imatinib mesylate in ocular melanoma and liposarcoma expressing immunohistochemical c-KIT (CD117). Ann Oncol 2003; 14:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/145\">",
"      de Jong FA, Kehrer DF, Mathijssen RH, et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 2006; 11:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/146\">",
"      Farrell CL, Bready JV, Rex KL, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/147\">",
"      Cao S, Troutt AB, Rustum YM. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res 1998; 58:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/148\">",
"      Michael M, Brittain M, Nagai J, et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol 2004; 22:4410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/149\">",
"      Takeda Y, Kobayashi K, Akiyama Y, et al. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 2001; 92:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/150\">",
"      Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 2007; 97:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/151\">",
"      Meropol NJ, Blumenson LE, Creaven PJ. Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. Am J Clin Oncol 1998; 21:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/152\">",
"      Rosenoff SH, Gabrail NY, Conklin R, et al. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial. J Support Oncol 2006; 4:289.",
"     </a>",
"    </li>",
"    <li>",
"     Hoff PM, Saragiotto DF, Barrios CH, et al. A randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial (abstract). J Clin oncol 2012; 30(suppl 4): abstract 549. file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=115&amp;abstractID=88684 (Accessed on March 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/154\">",
"      Talley NJ, Phillips SF, Haddad A, et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990; 35:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/155\">",
"      Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/156\">",
"      Sharma RK. Vincristine and gastrointestinal transit. Gastroenterology 1988; 95:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/157\">",
"      Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1986; 1:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/158\">",
"      Holland JF, Scharlau C, Gailani S, et al. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res 1973; 33:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/159\">",
"      Anderson H, Scarffe JH, Lambert M, et al. VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies. Hematol Oncol 1987; 5:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/160\">",
"      Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994; 21:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/161\">",
"      Haim N, Epelbaum R, Ben-Shahar M, et al. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 1994; 73:2515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/162\">",
"      Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/163\">",
"      Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/164\">",
"      Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/165\">",
"      Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108:3458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/166\">",
"      Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/167\">",
"      Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357:2123.",
"     </a>",
"    </li>",
"    <li>",
"     Prescribing information for pomalidomide available online at file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdf?et_cid=31038989&amp;et_rid=463638624&amp;linkid=www.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f204026lbl.pdf (Accessed on February 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/169\">",
"      Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/170\">",
"      Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2664.",
"     </a>",
"    </li>",
"    <li>",
"     Wells, SA, Robinson, BG, Gagel, RRF, et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA) (Abstract 5503). J Cliin Oncol 2010; 28:421s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=50718 (Accessed on April 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/172\">",
"      Weed HG. Lactulose vs sorbitol for treatment of obstipation in hospice programs. Mayo Clin Proc 2000; 75:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/173\">",
"      Aksoy DY, Tanriover MD, Uzun O, et al. Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis. Ann Oncol 2007; 18:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/174\">",
"      Krishna SG, Zhao W, Grazziutti ML, et al. Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications. Cancer 2011; 117:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/175\">",
"      Ibrahim NK, Sahin AA, Dubrow RA, et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 2000; 355:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/176\">",
"      Kreis W, Petrylak D, Savarese D, Budman D. Colitis and docetaxel-based chemotherapy. Lancet 2000; 355:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/177\">",
"      Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/178\">",
"      Emoto M, Kawarabayashi T, Hachisuga MD, et al. Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol 1996; 61:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/179\">",
"      Kamthan AG, Bruckner HW, Hirschman SZ, Agus SG. Clostridium difficile diarrhea induced by cancer chemotherapy. Arch Intern Med 1992; 152:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/180\">",
"      Husain A, Aptaker L, Spriggs DR, Barakat RR. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 1998; 71:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/23/42362/abstract/181\">",
"      McClay H, Cervi P. Thalidomide and bowel perforation: four cases in one hospital. Br J Haematol 2008; 140:360.",
"     </a>",
"    </li>",
"    <li>",
"     Link to 2009 FDA MedWatch announcement at www.fda.gov/medwatch/safety/2009/safety09.htm#Tarceva (Accessed on April 01, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2824 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42362=[""].join("\n");
var outline_f41_23_42362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H204887526\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1730603\">",
"      Specific drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - 5-Fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Predictive markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H717960356\">",
"      - DPD deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H44530683\">",
"      - TYMS gene variations",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H44530527\">",
"      - Other markers of 5-FU toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H44530323\">",
"      Pharmacogenetic testing for DPYD and TYMS variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H204886729\">",
"      Management of DPD-deficient patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H204886589\">",
"      - Uridine triacetate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pharmacokinetically-guided dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Capecitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H204890821\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ftorafur",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Irinotecan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      UGT1A1 polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Irinotecan plus 5-FU",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H717960378\">",
"      - IFL",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H717960451\">",
"      - FOLFIRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dose modifications for diarrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Oxaliplatin combinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Capecitabine plus oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pemetrexed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3597507\">",
"      - Cabazitaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H204887561\">",
"      - Bortezomib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H204887568\">",
"      - Vorinostat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Small molecule EGFR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Small molecule inhibitors of VEGFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bcr-Abl tyrosine kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Lapatinib and pertuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Temsirolimus and everolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Anti-EGFR monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Loperamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Octreotide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Other antidiarrheal agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Summary and consensus recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Investigational approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Is there a role for prophylaxis?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      CONSTIPATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Vinca alkaloids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Thalidomide and analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19930479\">",
"      Vandetanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      COLITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Neutropenic enterocolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Ischemic colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Clostridium difficile-associated colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Ipilimumab and immune-breakthrough enterocolitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      INTESTINAL PERFORATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Molecularly-targeted angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Thalidomide in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Erlotinib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H204887526\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2824\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2824|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?24/30/25062\" title=\"algorithm 1\">",
"      Management of cancer treatment-induced diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2824|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/60/23499\" title=\"table 1\">",
"      Common Terminology Criteria for Adverse Events diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/36/588\" title=\"table 2\">",
"      TheraGuide 5-FU test results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/29/20955\" title=\"table 3\">",
"      Treatment diarrhea pts on IFL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/24/32139\" title=\"table 4\">",
"      NCI CTCAE for NV v4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/16/7435\" title=\"table 5\">",
"      Eval cancer treatment induced diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/40/11915\" title=\"table 6\">",
"      Foods and drugs to avoid in CID",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=related_link\">",
"      Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32025?source=related_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44202?source=related_link\">",
"      Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=related_link\">",
"      Chemotherapy in castrate-resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7625?source=related_link\">",
"      Interleukin-2 and other immunotherapies for advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17962?source=related_link\">",
"      Investigational therapies in the medical management of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=related_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38250?source=related_link\">",
"      Oral toxicity associated with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39894?source=related_link\">",
"      Pathophysiology and prediction of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=related_link\">",
"      Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29528?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Single agent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=related_link\">",
"      Systemic treatment for unresectable malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16311?source=related_link\">",
"      The VIPoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=related_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21753?source=related_link\">",
"      Treatment of relapsed or refractory acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27125?source=related_link\">",
"      Typhlitis (neutropenic enterocolitis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_23_42363="Critical physical findings of trauma";
var content_f41_23_42363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical findings that indicate critical injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"3\">",
"        Vital signs and level of consciousness",
"       </td>",
"       <td>",
"        GCS &lt;14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shock (compensated or uncompensated)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RR lower or higher than normal for age&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"10\">",
"        Anatomy of injury",
"       </td>",
"       <td>",
"        Airway trauma with compromise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest trauma with respiratory compromise or shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain or distension with shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two or more proximal long-bone fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amputation proximal to wrist or ankle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crushed, mangled, or degloved extremity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Open or depressed skull fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paralysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penetrating trauma to head, neck, chest, abdomen, or proximal extremities",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GCS: Glasgow coma scale.",
"     <br>",
"      * Compensated shock presents with tachycardia and poor perfusion but normal blood pressure. Uncompensated shock manifests as tachycardia and signs of inadequate perfusion with hypotension for age (See text entitled \"Unique pediatric considerations\" for discussion of vital signs in children and shock).",
"      <br>",
"       &bull; See Unique pediatric considerations, section on pediatric physiology.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reference: American College of Surgeons Committee on Trauma. Resources for optimal care of the injured patient 2006. American College of Surgeons, Chicago, IL, 2006, p. 22.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42363=[""].join("\n");
var outline_f41_23_42363=null;
var title_f41_23_42364="Lake Louise AMS";
var content_f41_23_42364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lake Louise score for AMS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        The sum of response is the AMS Self-report score. Headache and at least one other symptom must be present for the diagnosis of AMS. A score of 3 or more is required for the diagnosis of AMS.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle2\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        1. Headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        None at all",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Mild headache",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Moderate headache",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Severe headache",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        2. Appetite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Good appetite",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Poor appetite or nausea",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Moderate nausea or vomiting",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Severe, incapacitating nausea and vomiting",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        3. Fatigue and/or weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Not tired or weak",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Mild fatigue/weakness",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Moderate fatigue/weakness",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Severe fatigue/weakness",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        4. Dizziness/lightheadedness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        None",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Mild",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Moderate",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Severe, incapacitating",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        5. Difficulty sleeping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Slept as well as usual",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Did not sleep as well as usual",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Woke many times, poor night's sleep",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Could not sleep at all",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total:",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Roach, RC, B&auml;rtsch, P, Oelz, O, Hackett, PH, Lake Louise AMS Scoring Consensus Committee. The Lake Louise acute mountain sickness scoring system. In: Hypoxia and Molecular Medicine, Sutton, JR, Houston, CS, Coates, G (Eds.), Charles S. Houston, Burlington, VT 1993. p.272-4.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42364=[""].join("\n");
var outline_f41_23_42364=null;
var title_f41_23_42365="Robot surg laparoscope";
var content_f41_23_42365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Robotic surgery laparoscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Intuitive Surgical, Inc, 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42365=[""].join("\n");
var outline_f41_23_42365=null;
var title_f41_23_42366="Calculator: Body mass index for adults (Patient information)";
var content_f41_23_42366=[" <div id=\"disclaimer\">",
"  The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"  <a href=\"/home/terms-use\" target=\"_blank\">",
"   UpToDate Terms of Use",
"  </a>",
"  &copy;2013 UpToDate, Inc.",
" </div>",
" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"BodyMassIndexPatient_form\" name=\"BodyMassIndexPatient_form\" onkeydown=\"clrResults();\" onkeyup=\"BodyMassIndexPatient_fx();\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Body mass index for adults (Patient information)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Body Mass Index (BMI) is a measure of weight in relation to height.  It is the most practical way to estimate if a person is underweight, at a healthy weight, overweight, or obese.",
"    </span>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Enter height and weight:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Height",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Height_foot_param\" onblur=\"BodyMassIndexPatient_fx(); minMaxCheck();\" onchange=\"BodyMassIndexPatient_fx();\" size=\"7\" type=\"text\"/>",
"            </td>",
"            <td align=\"left\">",
"             <span class=\"medCalcFontOneBold\">",
"              feet",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td>",
"             &nbsp;",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Height_inch_param\" onblur=\"BodyMassIndexPatient_fx(); minMaxCheck();\" onchange=\"BodyMassIndexPatient_fx();\" size=\"7\" type=\"text\"/>",
"            </td>",
"            <td align=\"left\">",
"             <span class=\"medCalcFontOneBold\">",
"              inches",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Weight",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Weight_param\" onblur=\"BodyMassIndexPatient_fx(); minMaxCheck();\" onchange=\"BodyMassIndexPatient_fx();\" size=\"7\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <span style=\"white-space: nowrap;\">",
"              <span class=\"medCalcFontOneBold\">",
"               pounds",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              BMI",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"BMI_param\" onfocus=\"blur();\" size=\"7\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"      <tr>",
"       <td bgcolor=\"#eeeeee\" width=\"1%\">",
"        <br/>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <span class=\"medCalcFontTitleBox\">",
"         Body Mass Index Interpretation",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"       <tr id=\"rr1_1\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          BMI &lt; 18.5:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Underweight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_2\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          BMI &gt;= 18.5 and &lt; 25:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Healthy weight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_3\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          BMI &gt;= 25 and &lt; 30:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Overweight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_4\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          BMI &gt;= 30:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Obesity",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). The practical guide: identification, evaluation, and treatment of overweight and obesity in adults.",
"        <i>",
"         Bethesda: National Institutes of Health",
"        </i>",
"        . 2000, NIH publication 00-4084.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42366=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function BodyMassIndexPatient_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.BodyMassIndexPatient_form){",
"",
"",
"doCalc = true;",
"inches = parseFloat(Height_inch_param.value);",
"if (isNaN(inches)) inches = 0;",
"param_value = (parseFloat(Height_foot_param.value) * 12) + inches;",
"Height = param_value;",
"if (Weight_param.value.indexOf(',') >= 0){ Weight_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"Weight = param_value;",
"dp = 1;",
"BMI =  (Weight/2.205) / power((Height/39.37), 2);",
"",
"if (doCalc) BMI_param.value = fixDP(BMI, dp);",
"",
"if (isNaN(BMI_param.value)) BMI_param.value = '';",
"",
"",
"if (doCalc){",
"",
"rrclr();",
"if (BMI < 18.5){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((BMI >= 18.5) && (BMI < 25)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if ((BMI >= 25) && (BMI < 30)){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"if (BMI >= 30){ document.getElementById('rr1_4').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BodyMassIndexPatient_form){",
"",
"if (Height_foot_param.value && Height_foot_param.value < 3) {",
"Height = 0;",
"Height_foot_param.value = \"\";",
"clrResults();",
"alert(\"Minimum input is 3 feet.\");",
"}",
"",
"if (Height_inch_param.value && Height_inch_param.value < 0) {",
"Height = 0;",
"Height_inch_param.value = \"\";",
"clrResults();",
"alert(\"Minimum input is 0 inches.\");",
"}",
"",
"if (Height_foot_param.value && Height_foot_param.value > 7) {",
"Height_foot_param.value = \"\";",
"clrResults();",
"Height = 0;",
"alert(\"Maximum input is 7 feet.\");",
"}",
"",
"if (Height_inch_param.value && Height_inch_param.value > 11) {",
"Height_inch_param.value = \"\";",
"clrResults();",
"Height = 0;",
"alert(\"Maximum input is 11 inches.\");",
"}",
"",
"if (Weight_param.value && Weight < 20) {",
"Weight = 0;",
"Weight_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Weight is 20 pounds.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Weight_param.value && Weight > 800) {",
"Weight_param.value = \"\";",
"clrResults();",
"Weight = 0;",
"doCalc = false;",
"alert(\"The maximum value for Weight is 800 pounds.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BodyMassIndexPatient_form){",
"",
"BMI_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f41_23_42366=null;
var title_f41_23_42367="Digital block great toe I";
var content_f41_23_42367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Great toe digital block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To perform a three-sided toe block or four-sided ring block, insert the needle just distal to the MTP (metatarsal/phalangeal) joint at the lateral edge of the toe. Slowly advance the needle straight from the dorsal to the plantar surface, injecting as the needle is advanced. This picture shows the position of the needle just after it has been inserted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Baldor, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_23_42367=[""].join("\n");
var outline_f41_23_42367=null;
